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Acetate is excreted as a metabolic end product in ma y microbes.  Acetate 
production has primarily been studied in bacteria and rchaea but is known to occur in 
eukaryotic organisms as well.  For example, acetate is one of the most abundant 
metabolites excreted by the fungal pathogen Cryptococcus neoformans during 
cryptococcosis suggesting that acetate production may be important during pathogenesis.  
One possible pathway for acetate production in C. eoformans involves the enzymes 
xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp), which can generate 
acetyl phosphate from either fructose 6-phosphate (F6P) or xylulose 5-phosphate (X5P), 
and acetate kinase (Ack), which can then convert actyl phosphate to acetate. C
neoformans has an ACK and two XFP open reading frames that we’ve designated as 
XFP1 and XFP2, and several studies indicate that these transcript  are expressed and/or 
upregulated under infectious conditions.  However, until now, the Xfp-Ack pathway in C. 
neoformans has not been studied. 
Here I describe the first characterization of a eukaryotic Xfp, the C. neoformans 
Xfp2.  C. neoformans Xfp2 was found to display both substrate cooperativity and 
allosteric regulation.   C. neoformans Xfp2 showed positive cooperativity in regards to 
F6P and X5P binding and negative cooperativity for Pi binding.  Activity was inhibited 
by ATP, phosphenolpyruvate (PEP), oxaloacetic acid (OAA) and glyoxylate and 
activated by AMP.  Both PEP and OAA were found to bind at the same or possess 
overlapping allosteric sites on the enzyme.   
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Prior to this characterization of C. neoformans Xfp2 the only other 
phosphoketolases characterized have been from bacteria, and none report the presence of 
substrate cooperativity or allosteric regulation.  Therefore, Lactobacillus plantarum Xfp 
was re-characterized to determine if the enzyme showed substrate cooperativity and/or 
allosteric regulation.  L. plantarum Xfp displayed negative cooperativity for Pi binding 
and was also allosterically inhibited by PEP, OAA and glyoxylate, but activity was 
unaffected by the presence of AMP or ATP.  Like C. neoformans Xfp2, PEP and OAA 
were found to share the same or overlapping allosteric sites on L. plantarum Xfp.  This 
study proved that substrate cooperativity and allosteric regulation exist for at least some 
bacterial Xfps.  
Models of C. neoformans Xfp2 monomer and dimer were generated from existing 
bacterial Xfp crystal structures.   Since bacterial and eukaryotic Xfps may share the 
PEP/OAA allosteric site, ligand docking simulations were performed with PEP and OAA 
in various proposed binding sites on the C. neoformans Xfp2 model.  Site-directed 
mutagenesis was performed on residues predicted to hydr gen bond with PEP and OAA 
within these sites.  However, these studies have yet to r veal the location of the 
PEP/OAA allosteric site.  More recently the Xfp2 dimer model has revealed new sites 
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LITERATURE REVIEW OF XYLULOSE 5-PHOSPHATE/ FRUCTOSE 6-
PHOSPHATE PHOSPHOKETOLASES FROM BACTERIA AND FUNGI 
 
I.  INTRODUCTION 
 
Acetate is excreted from the cell as a metabolic end product in many microbes of 
the Bacteria, Archaea and Eukarya.  Acetate excretion allows for the regeneration of 
NAD+ consumed during glycolysis, recycling of coenzyme A (CoASH) required for 
generating the central metabolic intermediate acetyl-CoA, and production of ATP under 
conditions in which the TCA cycle is not fully operational (1).  However, extracellular 
acetate dissociates, posing a problem to the cell by acidifying the surrounding 
environment, but one way the cell can overcome this problem is by importing 
extracellular acetate and utilizing it as a carbon s urce (2,3).  Therefore, cells must 
maintain a balance between acetate excretion and utilization.  The studies presented in 
this dissertation suggest that the regulation of this process is far more complex than 
anticipated.   
The primary pathways for acetate production in bacteria typically involve the 
enzyme acetate kinase (Ack) which converts acetyl phos hate to acetate and energy in 
the form of ATP (4).  Ack primarily partners with te acetyl phosphate producing 
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enzyme phosphotransacetylase (Pta), found in bacteri , one genus of methane producing 
archaea, and green algae, which generates acetyl phosphate from excess acetyl-CoA.  
Ack can also partner with xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase 
(Xfp), which is found in lactic acid bacteria and fungi that generate acetyl phosphate 
from pentose phosphate pathway end products xylulose 5-phosphate (X5P) or fructose 6-
phosphate (F6P) (4).  Additionally, both the Pta-Ack and Xfp-Ack pathways provide 
mechanisms for controlling cellular concentrations f acetyl-phosphate, which plays an 
important role in signal transduction (1).  Some bacteria including Escherichia coli have 
an acetate forming pyruvate oxidase (PoxB) that generates acetate from pyruvate (1).  
  Most studies of enzymes involved in acetate production have been in bacteria.  
However, acetate is a major metabolic end product in eukaryotic microbes as well, and 
many of the enzymes and pathways involved in acetate production in bacteria can be 
found in eukaryotic organisms (4-6).  This chapter b gins with a review of acetate 
production in bacteria, archaea, and eukaryotes.  Literature describing acetate production 
via the Xfp-Ack pathway (which until now had not been studied in eukaryotic microbes) 
will be focused on in this chapter and is the central theme throughout this dissertation.  
Also, a brief overview will be given on the pathogenic fungus Cryptococcus neoformans 
highlighting evidence of the utilization of the Xfp-Ack pathway during cryptococcal 
infections.      
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II.  ACETATE PRODUCTION 
 
Acetate Production in Bacteria 
 Many studies have focused on the production and utilization of acetate in bacteria.  
Bacterial cells perform what is referred to as the “acetate switch” in which cells transition 
from a condition of rapid growth, where acetate is xcreted, to a period of slow growth 
following the depletion of essential carbon sources, where cells begin to scavenge, import 
and utilize acetate as a carbon source, allowing growth to continue (1).  Acetogenesis, the 
excretion of acetate, occurs as a result of the needs to regenerate coenzyme A (CoASH) 
for acetyl-CoA production and NAD+ for glycolysis, and it provides a mechanism for 
generating ATP under conditions in which the TCA cycle is not fully functioning (1).  
The accumulation of both intracellular and extracellular acetate can be toxic to the cell 
(2,3).  Therefore, it is essential for cells to maint n a proper balance between the benefits 
of acetate production and excretion and the uptake and utilization of acetate as a carbon 
source when necessary.   
E. coli produces acetate aerobically during periods of rapid growth on glucose, 
which ultimately inhibits respiration, and anaerobically during mixed-acid fermentation 
(1,7).  Acetate is produced in E. coli through a pathway involving Pta (EC 2.3.1.8; Eq. 
1.1]) and Ack (EC 2.7.2.1; Eq. 1.2) (1,4,8) or by the enzyme pyruvate oxidase (PoxB, EC 
1.2.5.1; Eq. 1.3) (1).  In the absence of oxygen th Pta-Ack pathway also serves as a 
source of ATP when a branched form of the tricarboxylic acid (TCA) cycle is utilized 
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that does not generate energy (1).  Deletion of the Pta-Ack pathway in E. coli results in 
highly reduced acetate production but increased levels of formate and lactate (3) while 
deletion of PoxB primarily causes a reduction in biomass and growth efficiency under 
aerobic conditions (3,9) .  Therefore, the Pta-Ack pathway primarily contributes to 
acetate production during anaerobic fermentation while PoxB functions primarily under 
aerobic conditions.   In addition to redirecting acetyl-CoA overflow and generating ATP 
under hypoxic conditions, the Pta-Ack pathway also serves as the primary influence over 
intracellular acetyl phosphate concentrations.  Acetyl phosphate is a high-energy form of 
phosphate that plays important roles in signal transduction (1,10,11).  For example, signal 
transduction in bacteria often involves a two component signal transduction pathway.  
These two component signaling pathways typically involve the phosphorylation of a 
histidine kinase that in turn phosphorylates various response regulators resulting in the 
activation of the signaling pathway process (12-14).  It has been shown that acetyl 
phosphate can act as the phosphoryl donor for two component response regulators via 
direct phosphoryl transfer (14).  Additionally, acetyl phosphate has been found to 
regulate other important bacterial processes such as biofilm development (11) and 
flagellar expression (15).   
   acetyl-CoA + Pi ↔ CoA + acetyl phosphate             [Eq. 1.1] 
   acetyl phosphate + ADP ↔ acetate + ATP                         [Eq. 1.2] 
   pyruvate + ubiquinone + H2O → acetate + ubiquinol + CO2            [Eq. 1.3] 
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In addition to Pta, Ack can also partner with Xfp in lactic acid bacteria (16) and 
bifidobacteria (17).  Xfp generates acetyl phosphate from the pentose phosphate pathway 
end products X5P (EC 4.1.2.9; Eq. 1.4) and F6P (EC 4.1.2.22; Eq. 1.5) which can then be 
converted to acetate and ATP by Ack (Eq. 1.2) (4,17).  The Xfp-Ack pathway will be 
discussed in greater detail later on in this chapter.  Other enzymes that produce the Ack 
substrate acetyl phosphate include glycine reductase (EC 1.21.4.2; Eq. 1.6), and related 
enzymes sarcosine reductase (EC 1.21.4.3) and betaine reductase (EC 1.21.4.4), 
sulfoacetaldehyde acetyltransferase (Xsc; EC 2.3.3.15; Eq. 1.7), and acetyl phosphate 
forming pyruvate oxidase (Pox;  EC 1.2.3.3; Eq. 1.8).  These enzymes are present in 
various bacteria but are not found in E. coli, archaea, or eukaryotes. 
   xylulose 5-phosphate + Pi → acetyl phosphate + glyceraldehyde 3-phosphate   [Eq. 1.4] 
   fructose 6-phosphate + Pi → acetyl phosphate + erythrose 4-phosphate             [Eq. 1.5] 
   glycine + Pi + thioredoxin → acetyl phosphate + NH3 + thioredoxin disulfide   [Eq. 1.6] 
   2-sulfoacetaldehyde + Pi → acetyl phosphate + sulfite                                  [Eq. 1.7] 
   pyruvate + Pi + O2 → acetyl phosphate + CO2 + H2O2                                        [Eq. 1.8] 
Acetate Production in Archaea 
The Pta-Ack pathway is also found in one genera of methane producing archaea, 
Methanosarcina, where acetate is utilized to produce methane (18).  It has been shown in 
Methanosarcina thermophila that Ack and Pta are produced in greater quantities in cells 
grown on acetate versus methanol (19,20).  Since M. thermophila is a thermophile, the 
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Ack and Pta enzymes from this organism have been shown to be active at temperatures 
up to 70°C, but activity is greatly reduced at higher temperatures (19,20).  Additionally, 
gene knockouts of either Ack or Pta in Methanosarcina acetivorans prevents growth on 
acetate and carbon monoxide suggesting that both Ack and Pta are essential (21).  
Therefore, in Methanosarcina the Pta-Ack pathway primarily acts in the direction of 
acetate activation to acetyl-CoA rather than acetate production (22).  However, acetate 
and formate rather than methane are the primary metabolic end products of M. 
acetivorans grown on carbon monoxide suggesting that under this condition the Pta-Ack 
pathway acts in the direction of acetate and ATP production (21).   
Pyrococcus furiosus, a hyperthermophilic archaeon, has an ADP-forming acetyl-
CoA synthetase (Acd; EC 6.2.1.13; Eq. 1.9) that catalyzes, under physiological 
conditions, the reversible conversion of acetyl-CoA t  acetate and ATP (23).  P. furiosus 
can grow at temperatures up to 105°C, and Acd from this organism shows optimal 
activity at 90°C.  In addition to acetyl-CoA, Acd can also utilize propionyl-CoA (100%) 
and butyrl-CoA (92%) as substrates (23).  Acd was first described in P. furiosus but has 
since been discovered and characterized in some other archaea, including Archaeoglobus 
fulgidus (24), Methanococcus jannaschii (24), Haloarcula marismortui (25) and 
Pyrobaculum aerophilum (25).  





Acetate Production in Eukarya 
 Ack and partner enzymes were originally thought to exist only in bacteria and one 
genus of methane-producing archaea, but have more recently been identified in 
eukaryotic organisms as well (4,26).  The Pta-Ack pathway has been discovered in green 
algae and the oomycete Phytophthora (4) but has thus far only been studied in the green 
alga Chlamydomonas.  Acetate is a major fermentation product of Chlamydomonas 
grown under dark, anoxic conditions (27).  C reinhardtii has two Pta-Ack pathways, and 
it has been suggested that one may function in the direction of acetate activation while 
the other functions in the direction of acetate production (4), though more recent evidence 
contradicts this hypothesis (27).  Chlamydomonas RNA levels of Ack1, Ack2, Pta1 and 
Pta2 are increased following growth in dark, anaerobic conditions suggesting they are 
involved in the production of acetate and ATP under th se conditions (27).  More 
recently, it has been discovered that Ack1 and Pta2are localized to chloroplasts while 
Ack2 and Pta1 are localized to the mitochondria (Yang et al. Plant Cell in press).  A 
reduction of excreted metabolites was observed in all of the double and single mutations 
of these enzymes except for an ck2 single mutant suggesting that the C. reinhardtii 
chloroplast play the dominant role in acetate production under dark anoxic conditions.  A 
double mutation of ack1ack2 showed no acetate kinase activity; however acetate w s still 
produced and excreted under anoxic conditions suggestin  the presence of other acetate 
producing pathways in this organism (Yang et al., Plant Cell, in press).  Additionally, 
none of the C. reinhardtii ack/pta knockouts show a growth defect on acetate suggesting 
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that neither of the two Pta-Ack pathways contribute to acetate utilization (Yang et al., 
Plant Cell, in press) as previously suggested (4). 
 Even though ACK open reading frames (ORFs) have been identified in both 
euascomycete and basidiomycete fungi, a PTAORF has yet to be found (4).  Instead, all 
fungi with a ACK ORF have at least one and in some cases two XFP ORFs suggesting 
that Ack partners with Xfp in fungi as in lactic acid bacteria and Bifidobacteria (4).  
Additionally, fungi can generate acetate from pyruvate via the pyruvate dehydrogenase 
bypass utilizing the enzymes pyruvate decarboxylase (Pdc; EC 4.1.1.1; Eq. 1.10) and 
acetaldehyde dehydrogenase (Ald; EC 1.2.1.5; Eq. 1.11) (28,29).  A deletion of the 
acetaldehyde dehydrogenase genes ALD6 and ALD5 in Saccharomyces cerevisiae 
significantly decreases acetate production during anaerobic growth on glucose (29).  
Some fungi may also produce acetate using the AMP-forming acetyl-CoA synthetase 
(Acs; EC 6.2.1.1: Eq 1.12).  In Salmonella enterica Acs activity is regulated through post 
translational modification of Lys609.  Acetylation f this lysine residue reduced activity 
while activation of the acetylated enzyme required d acetylation by CobB, an NAD+ 
dependent deacetylase of the sirtuin (Sir2) family (30).  The same S. enterica Acs lysine 
residue is conserved in the fungal Aspergillus nidulans Acs.  Analysis of Acs purified 
from A. nidulans under both aerobic and anaerobic conditions showed that under 
anaerobic conditions Acs had a higher kinetic affinity (Km) for acetate over acetyl-CoA.  
Immunoblotting analysis of Acs from A. nidulans grown under anaerobic conditions with 
an anti-acetyl-lysine antibody showed it is acetylated on lysine residues, but the identity 
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of the acetylated lysine was not reported (31).  Therefore, A. nidulans Acs may function 
in the direction of acetate production upon acetylation under anaerobic conditions (31)  
   pyruvate → acetaldehyde + CO2                                                                                                   [Eq. 1.10] 
   acetaldehyde + NADP+ → acetate + NADPH + H+                                           [Eq. 1.1] 
   acetate + ATP + CoA ↔ acetyl-CoA + AMP + PPi                                           [Eq. 1.12] 
Acd, originally identified in thermophilic archaea, which can generate acetate 
from acetyl-CoA (Eq. 1.9), has been found in two amitochondriate protists, Giardia 
lamblia and Entamoeba histolytica (32).  G. lamblia Acd functions primarily in the 
direction of acetate formation, and despite utilizing various assays, acetyl-CoA forming 
activity has yet to be detected.  Enzymatic properties of Acd indicate that it serves as a 
primary source of ATP in G. lamblia (32).  Native E. histolytica Acd has also been 
characterized and found to require the presence of Pi, ADP and a divalent metal cation for 
activity.  E. histolytica Acd prefers magnesium, iron or manganese for the divalent metal 
cation, and is unable to utilize AMP and PPi  in place of ADP and Pi (33). 
Additional sources of acetate, other than those previously mentioned, have been 
identified in some parasitic helminthes (34), protists (34) and algae (35). An 
acetate:succinate CoA transferase (Asct; EC 2.8.3.8; Eq. 1.13), identified in some 
protists, including Fasciola hepatica, Trichomonas vaginalis, and Trypanosoma brucei, 
is responsible for acetate production in mitochondria-like organelles (34).  Additionally 
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some eukaryotic microbes contain an acyl-CoA hydrolase (Ach; EC 3.1.2.1; Eq. 1.14), 
which has been found to be responsible for acetate production in peroxisomes (34,35).          
   acetyl-CoA + succinate → acetate + succinyl-CoA                                     [Eq. 1.13] 
   acetyl-CoA + H2O → acetate + CoA                                                            [Eq. 1.14] 
Regulation of Acetate Producing Pathways  
In some bacteria it has been shown that the Ack partner enzyme Pta is 
allosterically regulated.  Allosteric enzymes are regulated by the binding of ligands that 
induce a conformational change influencing substrate binding and catalysis (36).  There 
are two types of Pta enzymes designated as PtaI and Pt II.  Only PtaII enzymes exhibit 
allosteric regulation.  PtaII enzymes consist of two domains while PtaI has only one 
domain.  Both PtaIs and PtaIIs share homology in their C-terminal domains, which 
contains the substrate binding site.  The N-terminal domain, present in PtaII but not in 
PtaI, is the primary contributor to PtaII allostery (37,38).  The allosteric nature of Pta has 
primarily been explored in E. coli (37) and S. enterica (38). In the direction of acetyl 
phosphate production, E. coli PtaII is inhibited by NADH and ATP and activated by 
pyruvate and phosphoenolpyruvate (PEP) (37). In the acetyl phosphate forming direction 
S. enterica PtaII is inhibited by NADH and ATP and activated by pyruvate, and studies 
suggest that the N-terminal domain serves as a sensor for these two ligands (38).  The 
intricate regulation of Pta, as demonstrated in Figure 1.1 showing the influences and 
effects of S. enterica PtaII regulation as it fits with overall cellular metabolism (38), 
suggests that PtaII serves as an important sensor of cellular energy status.  
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 Most of the characterized Ack enzymes have been shown to follow standard 
Michaelis-Menten kinetics; however a few studies suggest the presence of substrate 
cooperativity and allosteric regulation (39,40).  An older study from 1979 stated that 
Bacillus stearothermophilus Ack displayed sigmoidal kinetics for ATP binding in the 
direction of acetyl phosphate formation, but this enzyme did not display sigmoidal 
kinetics for substrates in the direction of acetate formation (39).  Additionally, B. 
stearothermophilus Ack activity in the acetyl phosphate forming direction was activated 
in the presence of fructose 1,6-bisphosphate (39).  Very recently, both Ack enzymes 
(designated as AckA1 and AckA2) from Lactococcus lactis were reported to be 
allosterically regulated (40).  In the direction of acetate formation, both L. lactis AckA1 
and AckA2 are inhibited by fructose 1,6-bisphosphate with half maximal inhibitory 
concentrations (IC50) of 17 mM and 43 mM, respectively.  The cleavage of fructose 1,6-
bisphosphate that occurs during glycolysis results in he products glyceraldehyde 3-
phosphate (G3P) and dihydroxyacetone phosphate (DHAP).  While DHAP had little 
effect on AckA1 and AckA2 activity, G3P inhibited both enzymes, but it inhibited 
AckA1 to a greater extent than AckA2.  Additionally, the downstream glycolysis 
intermediate PEP inhibits both AckA1 and AckA2 with IC50s of 15 mM and 18 mM, 
respectively (40).  The authors conclude that allosteric control of AckA1 and AckA2 by 
major glycolytic intermediates provides a mechanism by which L. lactis can 
instantaneously switch between homolactic and mixed aci  fermentation depending on 
the availability of quickly or slowly metabolized carbohydrate sources (40).     
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III.  XYLULOSE 5-PHOSPHATE/ FRUCTOSE 6-PHOSPHATE 
PHOSPHOKETOLASE (XFP) 
  
Xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp) is a thiamine 
pyrophosphate (TPP)-dependent enzyme that catalyzes the conversion of Pi and xylulose 
5-phosphate (X5P) or fructose 6-phosphate (F6P) to acetyl phosphate and glyceraldehyde 
3-phosphate (G3P) or erythrose 4-phosphate (E4P), respectively.  Xfp functions as a key 
enzyme of the phosphoketolase pathway in lactic acid bacteria, shown in Figure 1.2, (41) 
and the fructose 6-phosphate shunt in bifidobacteria (17).    Xfp was originally thought to 
exist only in bacteria, but XFP ORFs have more recently been identified in euscomyete 
and basidiomycete fungi as well (4).  Until now only Xfp from bacteria have been 
biochemically and kinetically characterized.  Native Xfp from Bifidobacterium animalis 
(17) along with recombinant Xfp from Lactobacillus plantarum (16), Bifidobacterium 
breve (42),  Lactococcus lactis (43), Leuconostoc mesenteroides (43) and Pseudomonas 
aeruginosa (43) have been purified and characterized.  All of these bacterial enzymes 
were reported to follow Michaelis-Menten kinetics and were found to possess dual 
substrate specificity for both F6P and X5P.  Most bacterial Xfps, with the exception of B. 
animalis Xfp (17), display higher affinity for the substrate X5P over F6P (16,43) (kinetic 
parameters for X5P were not reported for B. breve Xfp). 
An Xfp reaction mechanism originally proposed by Yevenes et al. (16) for L. 
plantarum Xfp has since been supported by the structure analysis of B. longum Xfp (44).  
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Yevenes et al. proposed that Xfp follows a ping pong bi bi kinetc mechanism depicted in 
Figure 1.3 (16).  In this mechanism, the phosphoketose substrate, in this case X5P, first 
interacts with enzyme bound TPP.  The TPP-X5P intermediate forms enzyme bound 2-
α,β-dihydroxyethylidene-TPP (DHETPP) following the dissociation of G3P.  DHETPP 
undergoes a dehydration reaction to form enzyme bound enolacetyl-TPP which 
undergoes ketonization to form enzyme bound 2-acetyl-thiamine pyrophosphate 
(AcTPP).  Following nucleophilic attack by inorganic phosphate (Pi), acetyl phosphate is 
released, and enzyme bound TPP is free to interact with additional substrate.  
Interestingly the proposed reaction mechanism suggests that the formation of G3P or E4P 
from the substrates X5P or F6P respectively occurs in the absence of Pi. 
To date only the structures of the B. breve Xfp (42) and the Bifidobacterium 
longum Xfp (44) have been reported.  Figure 1.4 shows the dimer (a) and monomer (b) 
structures of B. breve Xfp (42).  The Xfp structures show that the monomer consists of an 
N-terminal (PP domain), middle (PYR domain) and C-terminal domain with the active 
site located between the PP and PYR domain, and the minimum functional unit of the 
enzyme exists as a dimer.  TPP binds within a deep, narrow channel in a V-conformation 
leaving the reactive C2 atom exposed to solvent.  There are several active site residues 
conserved between Xfp and the related TPP dependent enzyme transketolase (TK), an 
enzyme of the pentose phosphate pathway that catalyzes the reversible reaction to convert 
X5P or ribose 5-phosphate to G3P or sedoheptulose 7-phosphate respectively.  One 
residue, Glu479, is found in most TPP dependent enzymes and activates TPP through the 
formation of a hydrogen bond between the Glu479 side chain and TPP’s N1' atom of 
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pyrimidine.  Replacement of Glu479 with Ala in B. breve Xfp (42) or Asp in B. longum 
Xfp (44) completely abolished activity.  Further analysis of conserved B. breve Xfp and 
S. cerevisiae TK histidine residues showed that alteration of these residues either severely 
reduced or completely abolished activity (Table 1.1) suggesting that at least the initial 
Xfp mechanism follows that of other TPP dependent enzymes (42).  The Xfp reaction 
differs from that of TK primarily by the dehydration of DHETPP and nucleophilic attack 
of AcTPP by Pi neither of which occur in the TK reaction.  A site is observed in the B. 
breve AcTPP intermediate Xfp structure that holds a water molecule believed to be 
derived from the dehydration of DHETPP.  A similar site is also found in TK, but in TK 
this site is located at a greater distance away from the DHETPP intermediate which may 
be why dehydration of DHETPP in TK does not occur.  Also, it has been proposed that 
the C-terminal domain of TK acts as a regulatory domain (45), and this could also be the 
case for the C-terminal domain of Xfp.  In summary, studies of B. breve and B. longum 
Xfp active sites in comparison with the related enzyme TK from S. cerevisiae have 
provided important information on how the Xfp reaction proceeds.     
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IV. CRYPTOCOCCUS NEOFORMANS 
 
Cryptococcus neoformans, a basidiomycete soil fungal pathogen, is the leading 
cause of fungal meningitis worldwide.  It was clinically identified as a human pathogen 
in 1894.  After undergoing several name changes, it was termed its current identification 
of C. neoformans around 1950 when many laboratory investigations of this organism 
began (46,47).  The onset of the AIDS pandemic brought with it a surge of cryptococcal 
infections (48,49).  The global burden of cryptococcal meningitis in 2006 was estimated 
to be around one million cases that resulted in approximately 625,000 deaths, most of 
which occurred in sub-Saharan Africa due to the heavy burden of HIV in this area (49).  
Cryptococcal meningitis causes more deaths in sub-Sarahan Africa than tuberculosis, 
which often receives far greater public attention (Figure 1.5) (49).  Current treatments for 
cryptococcal infections often involve a combination of amphotericin B and fluconazole 
both of which target ergosterol, a component of fungal membranes not present in plants 
or animals.  However, these drugs can exhibit potentially harmful side effects and 
treatment is often long term to prevent the reemergence of infection, especially in HIV 
patients (50).  
 Individuals come into contact with C. neoformans basidospores from 
environmental sources such as rotting trees and soil contaminated with bird guano, which 
is believed to provide a favorable growth environmet for this fungus (48,51).  Spores are 
inhaled into the lungs where they can cause an immediate infection that is often cleared 
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by host immune defenses, or the fungus can enter a do mant state while remaining in the 
host.  If an individual’s immune system later becomes compromised, the dormant form 
can re-emerge and potentially disseminate through the blood stream, cross the blood-
brain barrier, and cause cryptococcal meningitis (Figure 1.6) (51).  Originally C. 
neoformans was classified into four serotypes designated A, B, C and D, where serotype 
A was associated with C. neoformans var. grubii, serotype D was associated with C. 
neoformans var. neoformans and serotypes B and C were associated with C. neoformans 
var. gatti (47,51).  More recently C. neoformans var gatti has been recognized as the 
separate species C. gatti (52,53).  C. neoformans var. grubii and var. neoformans are 
encountered most often in isolates from infected AIDS patients (47,51).  Originally 
considered less virulent, C. gatti has begun to emerge as a pathogen of even 
immunocompetent individuals and was the cause of a recent outbreak of cryptococcal 
infections on Vancouver Island in British Columbia, Canada (54).  The progression of C. 
gatti as a pathogen of immunocompetent individuals is alarming considering it shares 
many characteristics known to contribute to pathogenicity in C. neoformans (55).   
A number of factors have been identified that aid in C. neoformans’ ability to 
combat and overcome host defenses.  One factor essential for C. neoformans 
pathogenicity is its ability to grow at 37 °C, the temperature encountered during 
infection, which is an unusual characteristic for a soil fungus (56).  For example, 
cryptococcal species Cryptococcus podzolicus, like C. neoformans and C. gatti possess 
other virulent attributes such as a protective capsule and melanin production, but it is 
incapable of growing at elevated temperatures and, therefore, does not cause infection 
17 
 
(56,57). C. neoformans is surrounded by a protective polysaccharide capsule that 
primarily protects the cell by limiting phagocytosis, the first line of host defense, and 
much research has been devoted towards understanding capsule synthesis and 
composition as drug targets for cryptococcal infections (58-61).  Additionally, C. 
neoformans produces and excretes several extracellular enzymes such as laccase, 
phospholipase B, and urease that have also been shown to aid in virulence (55).   Both 
laccase and phospholipase B are localized to the cell wall where laccase mediates 
melanin production and phospholipase B has been shown to aid in cell wall integrity (55).  
Additionally phospholipase B is secreted outside the cell and has been shown to aid in 
extracellular pulmonary dissemination by degrading lung surfactant and phagolysosomal 
membranes upon phagocytosis (55,62,63).  C. neoformans produces large amounts of 
urease that catalyzes the breakdown of urea to ammonia and carbamate which may 
enhance central nervous system invasion (55,64,65). 
In addition to mechanisms that aid in protection and defense from the hostile host 
environment, C. neoformans possesses a surprising tolerance to hostile environments as 
well.  It has been shown that C. neoformans can reside inside the acidic environment of 
the phagolysosome of human macrophages.  In fact, trea ment of phagolysosomes 
containing C. neoformans with chloroquine, which increases lysosomal pH, resulted in 
antifungal activity, suggesting that C. neoformans is highly adaptable to acidic pH and 
less tolerant to alkaline pH (66).  C. neoformans also produces and deposits melanin 
within its cell wall which provides a stable population of free radicals that is believed to 
confer protection from oxidative killing by macrophages (67).  C. neoformans’ ability to 
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reside within phagolysosomes has been proposed as a mechanism of crossing the blood 
brain barrier in what is termed a Trojan horse dissemination model (47).  In support of 
the Trojan horse dissemination model, cryptococcal laden monocytes have been found in 
the brain suggesting that they can cross the blood brain barrier in this manner (68). 
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V.  POSSIBLE ROLES OF ACETATE PRODUCING PATHWAYS INFUNGI 
  
Acetate has been identified as one of the two most abundant metabolites produced 
and excreted during cryptococcal infections (5,6); however, the role acetate plays 
particularly during infection remains unknown.  In addition to the metabolic benefits of 
acetate production, such as the generation of ATP and regeneration of coenzyme A, there 
is evidence that C. neoformans may excrete acetate as a means of acidifying the 
extracellular environment.  Alkaline pH has been attributed to the killing of C. 
neoformans within macrophages (66,69) suggesting that elevated pH may be harmful to 
C. neoformans cells.  Additionally, the pH of cryptococcomas has been found to be 
between 5.4 and 5.6 in vivo (6) which could be a direct result of excreted acetate.   
Several routes for acetate production exist in C. neoformans (Figure 1.7). The 
Xfp-Ack (Eq. 1.4, 1.5, and 1.1) pathway has been discovered as a possible source of 
acetate in basidiomycete and euscomycete fungi (4).  All fungi lack Pta, therefore, Ack is 
believed to partner with Xfp as part of a modified pentose phosphate pathway to generate 
acetate from pentose phosphate pathway products X5P or F6P.  Phylogenetic analysis of 
fungal Xfps shows that these sequences separate into two distinct clusters that have been 
designated as Xfp1 and Xfp2 (Ann Guggisburg, Tonya Taylor and Kerry Smith, 
unpublished data).  All fungi that have an Ack have t least one and in some cases, such 
as C. neoformans, two Xfp ORFs (4).  As with the yeast S. cerevisiae, acetate could be 
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produced in C. neoformans from pyruvate through the actions of Pdc (Eq. 1.10) and Ald 
(Eq. 1.11) (70).   
 Evidence for a role of an Xfp-Ack partnership in producing ATP under the 
hypoxic conditions encountered in infectious tissue in which oxidative phosphorylation is 
limited originates from RNA expression studies.  Both C. neoformans Xfp2 and Ack 
have been shown to be upregulated under hypoxic conditi s typically encountered in 
infectious tissue (71).  Additionally Xfp2 has been shown to be expressed in C.
neoformans cells collected from the lungs of infected mice; however this same study also 
shows elevated expression of Pdc, suggesting that the Pdc-Ald pathway could also be 
involved in acetate production under this condition (70).  Ack has been found to be 
expressed in C. neoformans following macrophage engulfment (72) suggesting that
acetate production and concomitant production of ATP by Ack may be advantageous in 
this harsh environment, which includes limiting oxygen and nutrient availability.  All of 
these studies suggest that an Xfp-Ack partnership may play both an important nutritive 
and mechanistic role in controlling surrounding environmental conditions to aid in cell 
survival within infectious tissue. 
Currently there have been no studies on the physiological role of Xfp in C. 
neoformans; however, a few studies provide some evidence of its role in other fungi.  An 
Xfp2 homolog in the insect fungal pathogen Metarhizium anisopliae is required for full 
virulence (73), providing the first physiological evidence that Xfp2 may be important 
during fungal infections.  The filamentous fungus Aspergillus nidulans has an Xfp1 and 
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Ack but no Xfp2.  Overexpression of Xfp1 in A. nidulans resulted in increased specific 
growth rate on xylose, glycerol and ethanol but hadno effect on growth on glucose (74).  
Therefore, Xfp1 was attributed to providing greater ca bon metabolism flexibility in A. 
nidulans for growth on non-optimal carbon sources.  The fission yeast 
Schizosaccharomyces pombe is the only yeast identified to have an Xfp, belonging to the 
Xfp1 family with no Ack, providing evidence of additional functions for Xfp besides 
acting as an Ack partner enzyme.  Microarray studies have indicated increased Xfp RNA 
levels in S. pombe following exposure to environmental stresses such as oxidative stress 
due to hydrogen peroxide, heavy metal stress by cadmium sulfate, heat shock stress, 
osmotic stress by sorbitol, and alkylating stress (75).  Additionally, a S. pombe Xfp 
mutant was capable of growing on rich YES (yeast extract-sucrose) medium containing 
glucose between 29 – 32 °C, however, the ability of this mutant to grow under stressful 
conditions has not been reported (76,77).  As studies continue to shed light on the 
physiological role of acetate production and possible roles of Xfp1, Xfp2, and Ack in 
fungi, biochemical knowledge is lacking in regards to the function of any of these 
enzymes in eukaryotic organisms. 
  In addition to the production of acetate, the transport and utilization of acetate as 
an alternative carbon source is important during C. neoformans infection as well.  The 
acetate transporter Ady2 along with the enzyme acetyl-CoA synthetase (Acs) have both 
been shown to be upregulated in C. neoformans cells collected from the lungs of infected 
mice (70), suggesting that C. neoformans takes up acetate and uses Acs to convert it to 
the central metabolic intermediate acetyl-CoA.  Deletion of C. neoformans Acs results in 
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poor growth on acetate, ethanol and glycerol (Figure 1.8a).  Also, Acs deletion mutants 
demonstrate attenuated virulence in a mouse inhalation model (Figure 1.8b) (70).  
Additionally, enzymes of the glyoxylate cycle, malate synthetase and isocitrate lyase, are 
also upregulated during infection (70,78).  The primary role of the glyoxylate cycle is to 
produce energy from simple two carbon molecules such as acetate and ethanol when 
glucose availability is limiting.  Further studies showed that C. neoformans isocitrate 
lyase deletion mutants were unable to grow on acetate as a sole carbon source yet 
demonstrated no defect in animal virulence models or a defect in growth within the 
macrophage.  Therefore, even though glyoxylate cycle enzymes are upregulated during 
infection, these enzymes are not required for continued pathogenesis (78).   
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TABLE 1.1  Kinetic parameters for B. breve Xfp wild type and variants  (Ref 42).  




FIG 1.1  S. enterica PtaII function and regulation
of PtaII by various metabolites and how PtaII fits into cellular energy metabolism in 
enterica.  Dashed lines with an arrow indicate a positive effect on PtaII activity while 
dashed lines with a blunt end indicate a
pyruvate and inhibited by ATP and NADH (Ref 38
this figure) 
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.  This figure depicts the regulation 
 negative effect.  S. enterica PtaII is activated by 






FIG 1.2  Glucose fermentation in 
towards the phosphoketolase enzyme within the phosphoketolase pathway of 
plantarum as a means of producing acetate during glucose fermentation.  (1) 
phosphoketolase, (2) transaldolase, (3) acetate kinase, (4) transketolase, (5) 
phosphoenolpyruvate carboxykinase, (6) malate dehydrogenase, (7) pyruvate 
carboxylase, (8) phosphenolpyruvate 
formate-lyase, (11) phosphotransacetylase, (12) bifunctional alcohol dehydrogenase/ 
acetaldehyde dehydrogenase, (13) lactate d
for the reuse of this figure). 
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Lactobacillus plantarum.  Green arrows point 
synthase, (9) pyruvate kinase, (10) pyruvate 






FIG 1.3  Xfp reaction mechanism.  
al. depicts Xfp catalyzed reacti
reuse of this figure). 
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This reaction mechanism proposed by Yevenes et 




FIG 1.4  Crystal structure of 
bound TPP.  The monomer is separated into three domains: N
(blue), Middle (Pyr) domain (yellow) and C
active site located between the PP and Pyr domain
the reuse of this figure). 
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B. breve Xfp homodimer (A) and monomer (B) with 
-terminal (PP) domain 
-terminal domain (purple).  TPP binds to the 




FIG 1.5  Comparison of the estimated number of deaths in Sub
to various infectious diseases
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-Saharan Africa due 





FIG 1.6  Infection pathway of 
host.  People come into contact with basidiospores from enviro mental sources.  Spores 
are inhaled into the lungs where they can cause immediate pulmonary infection or simply 
enter a dormant form.  If an individual becomes immunocompromised, the dormant form 
can cross the blood brain barrier through hematogenus dissemination and cause 
cryptococcal meningitis (Ref. 51
37 
Cryptococcus neoformans from the environment to the 





FIG. 1.7.  Sources of acetate in 
neoformans via the Xfp-Ack pathway, the Pdc
(Enzyme abbreviations are indicated in the text).  
the top of this figure because it is the pathway focused on throughout this dissertation.  
(unpublished data, permission granted for the reuse of this figure by K. Smith).  
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C. neoformans.  Acetate can be produced in 
-Ald pathway or the enzyme Acs.  







FIG 1.8  Comparison of C. neoformans
recomplementation (acs1 + 
sodium acetate, glycerol and ethanol while the ability to grow on these carbon sources is 
regained upon ACS1 complementation (
results in attenuated virulence in a mous
granted for the reuse of this figure).
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 WT, Acs1 deletion (acs1), and Acs1 
ACS1) strains.  Deletion of ACS1 (acs1) inhibits growth on 
acs1 +ACS1) (A).  Deletion of ACS1
e inhalation model (B). (Ref. 70) (Permission 
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PHOSPHATE/ FRUCTOSE 6-PHOSPHATE PHOSPHOKETOLASE 2 (XFP2) FROM 
CRYPTOCOCCUS NEOFORMANS 
 
Katie Glenn, Cheryl Ingram-Smith, and Kerry S. Smith 
 
I.  ABSTRACT 
 
Xylulose 5-phosphate/fructose 6-phosphate phosphoketolas  (Xfp), previously 
thought to only be present in bacteria but recently found in fungi, catalyzes the formation 
of acetyl phosphate from xylulose 5-phosphate or fructose 6-phosphate.  Here we 
describe the first biochemical and kinetic characterization of a eukaryotic Xfp, that from 
the opportunistic fungal pathogen Cryptococcus neoformans, which has two XFP genes 
(designated XFP1 and XFP2). Our kinetic characterization of C. neoformans Xfp2 
indicated the existence of both substrate cooperativity for all three substrates and 
allosteric regulation through the binding of effector molecules at sites separate from the 
active site.  Prior to this study Xfp enzymes from two bacterial genera had been 
characterized and were determined to follow Michaelis-Menten kinetics.  C. neoformans 
Xfp2 is inhibited by ATP, phosphoenolpyruvate (PEP) and oxaloacetic acid (OAA) and 
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activated by AMP.  ATP is the strongest inhibitor with a half maximal inhibitory 
concentration (IC50) of 0.6 mM.    PEP and OAA were found to share the same or have 
overlapping allosteric binding sites while ATP binds at a separate site.  AMP acts as a 
very potent activator; as little as 20 µM AMP is capable of increasing Xfp2 activity by 
24.8 ± 1.0% while 50 µM prevented inhibition by 0.6 mM ATP.  AMP and PEP/OAA 
operated independently, with AMP activating Xfp2 and PEP/OAA inhibiting the 
activated enzyme.  This study provides valuable insight into the metabolic role of Xfp 
within fungi, specifically the fungal pathogen Cryptococcus neoformans, and suggests 




II.  INTRODUCTION 
 
Cryptococcus neoformans, an invasive opportunistic pathogen of the central 
nervous system, is the most frequent cause of fungal meningitis resulting in more than 
625,000 deaths per year worldwide (1,2).  Exposure to C. neoformans is common, as it is 
an environmental fungus found in the soil and can enter the lungs through inhalation, 
leading to pulmonary infection.  An increased rate of infection occurs in individuals with 
impaired cell-mediated immunity, particularly those with AIDS and recipients of 
immunosuppressive therapy. 
 Acetate has been shown to be a major metabolite reeas d by Cryptococcus during 
infection (3-5), but the significance of this is not known.  Genes encoding enzymes from 
three putative acetate-producing pathways and two putative acetate transporters have 
been shown to be upregulated during cryptococcal infection (6), suggesting acetate 
production and transport may be a necessary and required part of the pathogenic process. 
 One pathway for acetate production is composed of the enzymes xylulose 5-
phosphate/ fructose 6-phosphate phosphoketolase (Xfp) and acetate kinase (Ack). Xfp 
catalyzes the breakdown of xylulose 5-phosphate (X5P; X5P + Pi ↔ acetyl-phosphate + 
glyceraldehyde 3-phosphate; EC 4.1.2.9) or fructose 6-phosphate (F6P; F6P + Pi ↔ 
acetyl phosphate + erythrose 4-phosphate; EC 4.1.2.22)   Ack utilizes the acetyl 
phosphate product of the reaction to produce acetate + ATP (acetate + ATP ↔ acetyl 
phosphate +ADP; EC 2.7.2.1). These enzymes form a modified pathway, termed the 
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pentose phosphoketolase pathway, in lactic acid bacteri  and bifidobacteria (7).  This 
pathway is utilized in the heterofermentative degradation of pentoses and hexoses to the 
end products CO2, ethanol, acetate and lactate (8).  Xfp can convert X5P generated at the 
end of the oxidative phase of the pentose phosphate pathway to glyceraldehyde 3-
phosphate, which can enter the glycolytic pathway, and acetyl phosphate, which Ack can 
convert to acetate to generate ATP. 
 Only the Xfp enzymes from the lactic acid bacteria Bifidobacterium species and 
Lactobacillus plantarum have been purified and kinetically characterized (7,9).  The 
characterized bacterial Xfp enzymes show dual substrate specificity with X5P and F6P 
and follow Michaelis-Menten kinetics (7,9,10).  Here we report the first biochemical and 
kinetic characterization of eukaryotic Xfp, the C. neoformans Xfp2 (Accession # 
CNAG_06923.7).  Unlike the previously characterized bacterial Xfp enzymes, C. 
neoformans Xfp2 displays both substrate cooperativity and allosteric regulation.  The 
enzyme is inhibited by ATP, phosphoenolpyruvate (PEP) and oxaloacetic acid (OAA) 




III.  MATERIALS AND METHODS 
 
Materials  
Chemicals were purchased from Sigma Aldrich, VWR, or Fisher Scientific.  
Oglionucleotide primers were purchased from Integrated DNA Technologies.  Codon-
optimized C. neoformans XFP2 was synthesized by GenScript and supplied in the E. coli 
expression vector pET21b which provides for addition of a C-terminal His-tag for nickel 
affinity column purification.  
Production and Purification of C. neoformans Xfp2 
The recombinant plasmid pET21b-XFP2 was transformed into Escherichia coli 
RosettaBlue (DE3) placI (Novagen).  The recombinant strain was grown in Luria-Bertani 
(LB) medium with 50 µg/mL of ampicillin and 34 µg/mL of chloramphenicol at 37°C to 
an absorbance of ~0.8 at 600 nm, and production of the enzyme was induced by the 
addition of IPTG to a final concentration of 1 mM.  Cultures were incubated overnight at 
ambient temperature and cells were harvested by centrifugation and stored at -20°C prior 
to protein purification. 
Cell-free extract was prepared by first suspending the cells in buffer A (25 mM 
Tris, 150 mM sodium chloride, 20 mM imidazole, 1 mM dithiothreitol (DTT) and 10% 
glycerol [pH 7.4]), and passing twice through a French pressure cell at approximately 130 
MPa.  The cell extract was clarified by ultracentrifugation at 100,000 x g for 1 hour, and 
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then subjected to column chromatography using an AKT -FPLC (GE Healthcare).  Cell-
free extract was applied to a 5 mL His-Trap HP column (GE Healthcare).  After a 6 to 7 
column volume wash with buffer A to remove any unbound protein, the column was 
developed with a linear gradient from 0 to 0.5 M imidazole in buffer A.  Appropriate 
fractions determined to contain Xfp2 by SDS-PAGE and ctivity assays were pooled and 
dialyzed overnight in buffer containing 25 mM Tris, 10% glycerol and 1 mM DTT [pH 
7.0].  Aliquots of purified protein were stored at -80°C.  Protein concentration was 
determined using a modified Bradford assay with bovine serum albumin standards. 
Hydroxamate Assay Measuring Acetyl Phosphate Production  
Enzymatic activity was measured using the hydroxamate assay to quantitate the 
production of acetyl phosphate (9,11).  Standard reactions consisted of 0.5 mM thiamine 
pyrophosphate (TPP), 1 mM DTT, 5 mM magnesium chloride, and 50 mM MES buffer 
(pH 5.5 for all kinetic studies), with the concentration of substrates varied. The sodium 
phosphate substrate was used at a pH of 5.5.  
Reactions (200 µL) were initiated by the addition of enzyme and incubated at 40 
°C.  After 30 minutes, 100 µL of 2 M hydroxylamine hydrochloride (pH 7.0) was added 
and the reactions were allowed to incubate at room temperature for 10 minutes.  
Reactions were terminated by the addition of 600 µL of a 50:50 mixture of 2.5 % FeCl3 
in 2N HCl and 10% trichloroacetic acid to form the ferric-hydroxamate complex which 
was measured spectrophotometrically at 540nm (7,12).  Reactions were performed in 





Apparent kinetic parameters were determined by varying the concentration of one 
substrate with the other substrate held constant at a s urating level (60 mM for Pi or 
F6P). All substrates exhibited varying degrees of co perativity, and kinetic parameters 
were determined by fitting the data to the Hill equation [Eq. 2.1] (13,14) in which V0 is 
initial velocity, [S] is substrate concentration, V is maximum velocity, K0.5 is substrate 
concentration at half maximal velocity and h is the Hill constant.  Data was plotted using 
the scientific graphing program Kaleidagraph (Synergy Software). 





                           [Eq. 2.1] 
Determination of IC50 Values and Allosteric Binding Site Sharing of Xfp2 Inhibitors  
After determining kinetic parameters for X5P commercial availability was 
discontinued, so our investigations into the allosteric regulation of Xfp2 were performed 
only with F6P.  Half maximal inhibitory concentrations (IC50) were determined for all 
Xfp2 allosteric inhibitors by measuring the decrease in activity as a function of increasing 
inhibitor concentration.  GraphPad Prism 5 software was used to determine IC50 values 
by fitting the data with a log [inhibitor] vs. response curve.  In order to determine if any 
of the inhibitors bind at the same allosteric site or have overlapping allosteric sites, the 




IV.  RESULTS 
 
Optimization of reaction conditions 
An E. coli codon-optimized XFP2 (GenScript Inc.) was cloned into pET21b (C-
terminal His tag) and the recombinant enzyme was produced and purified by nickel 
affinity chromatography to electrophoretic homogeneity.  Optimal reaction conditions for 
purified Xfp2 activity were determined.  The temperatu e optimum was found to be 37-
40°C (Fig. 2.1A), the temperature that C. neoformans would be exposed to during 
infection.  Xfp2 had highest activity between pH 4.5 and 6.0 (Fig. 2.1B), and pH 5.5 was 
used when determining kinetic parameters.  Like its bacterial counterpart, C. neoformans 
Xfp2 requires the cofactor thiamine pyrophosphate (TPP), and 0.5 mM TPP was 
sufficient for full enzymatic activity (data not shown).  Xfp2 prefers Mg2+ as the divalent 
cation, but can also utilize Ca2+, Co2+, Mn2+, and Ni2+ (Fig. 2.1C).    
Kinetic characterization of C. neoformans Xfp  
In determining the kinetic parameters in the acetyl phosphate-forming direction, 
plots of substrate concentration versus velocity were found to be sigmoidal rather than 
hyperbolic as would be expected for enzymes following Michaelis-Menten kinetics.  This 
is the first demonstration of the existence of substrate cooperative binding among Xfp 
enzymes which was not reported in previous characteriza ions of bacterial Xfps (7,9,10). 
Apparent kinetic parameters (Table 2.1) were determined by fitting experimental data to 
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the Hill equation [Eq 2.1] in which a Hill constant greater than 1.0 represents positive 
cooperativity and a Hill constant less than 1.0 represents negative cooperativity (15,16)  
Xfp2 exhibits positive cooperativity (h >1.0) for both X5P and F6P, suggesting that 
binding of either of these substrates causes a favorable conformational change that 
facilities the binding of additional substrate at separate active sites on the enzyme.  Xfp2 
displays negative cooperativity (h < 1.0) for Pi with an average Hill constant of 
approximately 0.6.  The 2.6-fold higher catalytic efficiency suggests that X5P is slightly 
preferred over F6P.   
Allosteric Inhibitors  
Since we hypothesize that the Xfp-Ack pathway plays  significant role in ATP 
production during infection, it would seem likely that this pathway would be regulated, 
particularly since the F6P substrate of Xfp2 is an intermediate in glycolysis, another key 
ATP-generating pathway that has been shown to be critical for virulence (17). ATP along 
with coenzymes and intermediates from glycolysis and the tricarboxylic acid (TCA) 
cycle were tested to see if Xfp2 is allosterically regulated by these molecules.  Of the 
ligands tested, ATP, phosphoenolpyruvate (PEP), and oxaloacetic acid (OAA) were 
found to display the most pronounced inhibition (Fig. 2.2) while citrate caused slight 
inhibition (data not shown).  Acetyl-CoA, CoA, and pyruvic acid were also tested and 
had no effect on activity.  Progress curves for both substrates Pi and F6P were generated 
in the presence of increasing concentrations of ATP(Fig. 2.3A & B), PEP (Fig. 2.4A & 
B), and OAA (Fig. 2.5A & B).   
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For each of the three inhibitors, the K0.5 for Pi was not significantly affected (data 
not shown); however, the K0.5 concentrations for F6P increased in each case.  Th K0.5 for 
F6P increased from 15.9 ± 1.3 mM in the absence of inhibitor to 73.9 ± 3.2 mM in the 
presence of 9 mM ATP, 109.4 ± 6.9 mM in the presence of 15 mM OAA, and 69.3 ± 9.6 
mM in the presence of 16 mM PEP.  The addition of inhibitor also generated a more 
sigmoidal F6P progress curve that is reflected by the increase in the Hill coefficient.  The 
Hill coefficient increased from 1.41 ± 0.11 to 4.50 ± .20, 2.32 ± 0.07, and 2.40 ± 0.30 in 
the presence of 9 mM ATP, 15 mM OAA and 16 mM PEP respectively.  This suggests 
that the binding of ATP, PEP and OAA has a direct effect on the binding of F6P to the 
active site in order to more closely regulate Xfp2 activity in response to changing cellular 
concentrations of these effectors.  
The IC50 concentrations, the concentration of inhibitor required to reduce activity 
to half its maximally inhibited value, were determined for each inhibitor using the K0.5 
concentrations of both Pi (13 mM) and F6P (16 mM) (Table 2).  The IC50 value of 0.6 
mM for ATP is much lower than those determined for PEP and OAA, which were very 
similar (Table 2.2).  Since both molecules are similar in size and structure, it is possible 
that they bind at the same allosteric site.  In order to test if the inhibitors share the same 
allosteric site, reactions were performed in which one inhibitor was held constant at its 
IC50 concentration and the concentration of the second inhibitor was varied.  If two 
inhibitors bind at the same site (or if binding of one inhibitor occludes the binding of the 
second) then approximately half of the binding sites would be occupied by the first 
inhibitor, thereby lowering the concentration of the second (varied) inhibitor required to 
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inhibit activity by an additional 50%.  The IC50 of PEP decreased by approximately half 
in the presence of OAA; likewise the IC50 value of OAA decreased by about half in the 
presence of PEP (Table 2.2).  This suggests that PEP and OAA share the same allosteric 
site. Alternatively, PEP and OAA bind at separate ov rlapping sites in which the binding 
of one inhibitor prevents the binding of the second inhibitor.  The IC50 of PEP in the 
presence of ATP did not change significantly suggesting that the PEP/OAA site(s) is 
separate from the ATP allosteric site.   
Allosteric Activator 
C. neoformans Xfp2 is activated by the presence of AMP (Fig 2.6).  The presence 
of as little as 20 µM AMP resulted in elevated enzymatic activity that reached a 
maximum at 0.5 mM AMP.  The half maximal activation concentration was determined 
to be 29.7 ± 1.5 µM.  The effect of AMP activation  Pi and F6P progress curves was 
evaluated.  Increasing amounts of AMP resulted in increased Xfp2 activity at all Pi 
concentrations without affecting the overall shape of the curve or the K0.5 of Pi (Fig. 
2.6A).  Therefore, AMP does not appear to have a direct effect on the binding of Pi to the 
active site.  The presence of AMP decreased the K0.5 for F6P from 15.9 ± 1.3 mM in the 
absence of AMP to 9.1 ± 0.6 mM in the presence of 0.5 mM AMP.  Increasing 
concentrations of AMP resulted in more hyperbolic F6P progress curves (Fig. 2.6B).  The 
Hill coefficient decreased from 1.41 ± 0.11 in the absence of AMP to 0.97 ± 0.03 in the 
presence of 0.5 mM AMP, suggesting more constant affi ity for the substrate F6P.   
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 AMP not only causes activation but alleviates the eff cts of allosteric inhibitors 
(Fig. 2.7).  The presence of AMP completely prevents or overrides the inhibitory effect of 
ATP.  However, AMP cannot overcome inhibition by PEP.  The results observed are 
consistent with AMP and PEP acting separately, withAMP fully activating the enzyme, 
and PEP inhibiting from this fully activated level.  When ATP and PEP are both present, 
inhibition is slightly additive compared to the inhbition by either one alone. Activity 
decreased from 43.4 ± 0.7% in the presence of PEP to 32.5 ± 0.6% when both ATP and 
PEP are present.  The level of activity observed when AMP was present in addition to 
PEP was similar to that when AMP was present with bot  ATP + PEP.  In both cases, 
activity was in the range expected for inhibition of the fully activated enzyme by the IC50 




V.  DISCUSSION 
 
Here we report the first characterization of C. neoformans Xfp2, the first 
eukaryotic Xfp to be characterized.  Xfp functions with Ack in heterofermentative 
bacteria to form a modified pentose phosphoketolase p thway.  This pathway was 
originally thought to be present only in bacteria but has been more recently identified in 
euascomycete and basidiomycete fungi (18).  Like C. neoformans, many fungi with this 
pathway have two XFP ORFs designated as XFP1 and XFP2. 
 Unlike previously characterized bacterial Xfps, C. neoformans Xfp2 displays both 
substrate cooperative binding and allosteric regulation.  Xfp2 is allosterically regulated 
by the activator AMP and inhibitors ATP, PEP and OAA.  PEP and OAA appear to share 
the same allosteric binding site while ATP and AMP bind at a separate site.  The simplest 
explanation of AMP’s ability to fully overcome ATP inhibition is that they bind at the 
same site however our results do not conclusively rule out separate but interacting 
binding sites.  Xfp2 activation by AMP and inhibition by ATP is consistent with Xfp2 
partnering with Ack as part of a modified pentose phosphate pathway to generate ATP 
and acetate from X5P and F6P.  The intracellular ATP: MP ratio provides an indication 
of the cellular energy status and regulation of the Xfp2-Ack pathway by ATP and AMP is 
a way to modulate ATP production by this pathway.  High ATP levels indicate the energy 
needs of the cell have been satisfied and thus additional ATP production via the Xfp2-
Ack pathway is not necessary, whereas high AMP levels indicate an energy deficit and 
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the need for increased ATP production via the Xfp2-Ack pathway. A possible 
explanation for Xfp2 inhibition by PEP and OAA is tha  high concentrations of these 
intermediates from glycolysis and the TCA cycle respectively, are also signals that 
cellular energy needs have been met, and the cell can switch from glycolysis, which 
produces ATP and utilizes glucose, to gluconeogenesis to synthesize and store glucose. 
 A ping pong bi bi mechanism was originally proposed for Lactobacillus 
plantarum Xfp by Yevenes and Frey (9) in which enzyme bound TPP first interacts with 
F6P to form a TPP-F6P complex and release the product erythrose 4-phosphate (E4P) 
forming enzyme bound 2-α,β-dihydroxyethylidene-TPP (DHETPP).  DHETPP undergoes 
a dehydration reaction to form enzyme bound enolacetyl-TPP where ketonization 
converts it to enzyme bound acetyl-TPP (AcTPP).  AcTPP is phosphorylated and acetyl 
phosphate is released leaving TPP available to interact with additional F6P substrate and 
repeat the reaction.  Therefore, the product E4P is formed by the interaction of TPP and 
F6P in the absence of the second substrate Pi.  The crystal structure of Bifidobacterium 
longum Xfp confirmed the reaction mechanism proposed by Yevenes and Frey (19).  We 
suspect that C. neoformans Xfp2 follows the same active site reaction mechanism as the 
bacterial Xfps but with the added complexity of allosteric regulation that influences 
substrate-binding affinity.  Since all allosteric effectors were found to directly affect F6P 
binding, the binding of these effectors influences the interaction between F6P and TPP in 
the first step of the reaction mechanism.  We found that the presence of allosteric 
effectors do not influence the binding of Pi which further confirms and supports the 
existence of a ping pong bi bi mechanism in which the interaction between TPP and F6P 
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to form E4P occurs in the absence of Pi and that it is this first step of the reaction that is 
allosterically regulated.  
Acetate is the most abundant metabolite produced during cryptococcal pulmonary 
infection, but the role acetate plays in metabolism and infection is unknown (3-5).  
Genomic expression studies provide evidence that the Xfp-Ack pathway could be 
responsible for acetate production.  Serial analysis of gene expression on C. neoformans 
cells collected from the lungs of infected mice showed elevated expression of XFP2 (6).  
XFP2 was also found to be among the genes upregulated under hypoxic conditions that 
occur in infected tissue (20).  RNA microarray analysis of C. neoformans gene 
expression within the macrophage also indicates that Ack is expressed under this 
condition but Xfp2 was not present in this microarray data set (21).  In addition an Xfp2 
homolog is required for full virulence in the insect fungal pathogen Metarhizium 
anisopliae (22).  Taken together these studies suggest that C. neoformans Xfp2 may play 
a role during infection. 
 C. neoformans Xfp2 shows maximal activity between 37 - 40°C which is 
consistent with a role of Xfp2 during C. neoformans infection (23).   The Xfp-Ack 
pathway could serve as a source of ATP production under the hypoxic and acidic 
conditions encountered in the macrophage where ATP generation by oxidative 
phosphorylation is suppressed.  In addition, the pH of cryptococcomas has been found to 
be between 5.4 and 5.6 in vivo (4).  It is possible that the production and excretion of 
acetic acid generated by the Xfp-Ack pathway contribu es to the acidic environment of 
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cryptococcomas.  This acidic environment can aid in C. eoformans urvival outside the 
macrophage by inducing neutrophil necrosis and decreasing superoxide production (4).  
Our studies show that Xfp2 functions best at low pH with activity decreasing as pH 
increases.  Even in vitro assays of the bacterial Xfps were performed below neutral pH, 
between pH 6.0 (9) and 6.5(7), and optimal pH was not reported.   The intracellular pH of 
C. neoformans during infection is unknown, but even though C. neoformans cells are 
tolerant to low pH (24), it is unlikely that Xfp2 is exposed to low pH in vivo.  The 
presence of AMP can increase Xfp2 activity from 13.4 ± 0.7 % to 117.0 ± 2.0 % in the 
presence of 0.5 mM AMP at pH 7 with 100% activity considered to be the activity at pH 
5.5 using K0.5 substrate concentrations (K. Glenn and K. Smith, unpublished data), so 
pH could provide an additional means of regulating Xfp2 activity. 
The allosteric regulation that has evolved for C. neoformans Xfp2 versus its 
bacterial homolog seems to support a more complex rol  for this enzyme within fungal 
metabolism and during infection.  However, allosteric regulation by PEP and OAA but 
not AMP and ATP may be occurring with at least some bacterial Xfps (K. Glenn and K. 
Smith unpublished data).  We believe that Xfp2 partners with Ack to generate ATP, 
which is supported by the findings that Xfp2 is regulated by both ATP and AMP levels.  
The biochemical properties of this enzyme suggest that i  utilizes its partnership with Ack 
to generate ATP during infection and within the human macrophage where hypoxic 
conditions are encountered that limit ATP production by the electron transport chain.  
Xfp2’s involvement in C. neoformans metabolism especially during infection lends 
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support to future studies that focus on this enzyme as a possible drug target in the 
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TABLE 2.1.  Apparent kinetic parameters for C. neoformans Xfp2 
 




F6P 15.9 ± 1.3 3.47 ± 0.10 0.22 ± 0.01 1.41 ± 0.11 
X5P 6.4 ± 0.2 3.76 ± 0.05 0.58 ± 0.01 1.17 ± 0.06 













TABLE 2.2.  Half maximal inhibitory (IC50) concentrations 
 
Inhibitor (Varied) Inhibitor (Constant) IC50 
ATP -------- 0.61 ± 0.04 
 
PEP 
-------- 8.23 ± 0.09 
OAA 4.84 ± 0.07 
ATP 9.85 ± 0.25 
OAA 
-------- 7.50 ± 0.40 










FIG 2.1.  Optimization of Xfp2 reaction conditions.  Xfp2 activity was determined in 
the presence of saturating Pi (60 mM) and F6P (80 mM) substrate concentrations fr each 
reaction condition tested.  Activities are reported as percentage of the maximal activity 
determined during each assay.  (a) Temperature optima for Xfp2.  Enzyme reactions were 
performed at the indicated temperatures in triplicate.  (b) pH optima for Xfp2.  Enzyme 
reactions were performed utilizing 50mM MES (●) and 50 mM MOPS (○) over a range 
of pH values. (c) Divalent cation metal specificity for Xfp2.  Enzyme reactions were 








FIG 2.2.  Effect of various ligands on Xfp2 activity.  Various coenzymes and metabolic 
intermediates were tested for their effect on Xfp2 activity.  Activities are reported as 






FIG 2.3.  Effect of ATP on substrate progress curves.  Progress curves were generated 
in the presence of 0 mM (●), 3 mM (○), 6 mM (■) and 9 mM (□) ATP for the substrates 
Pi (a) and F6P (b).  Activities are reported in micromoles acetyl phosphate produced, and 







FIG 2.4.  Effect of PEP on substrate progress curves.  Progress curves were generated 
in the presence of 0 mM (●), 8 mM (○), and 16 mM (■) PEP for the substrates Pi (a) and 
F6P (b).  Activities are reported in micromoles acetyl phosphate produced, and enzyme 







FIG 2.5.  Effect of OAA on substrate progress curves.  Progress curves were generated 
in the presence of 0 mM (●), 7.5 mM (○), and 15 mM (■) OAA for the substrates Pi (a) 
and F6P (b) Activities are reported in micromoles acetyl phosphate produced, and 







FIG 2.6.  Effect of AMP on substrate progress curves.  Progress curves were 
generated in the presence of 0 mM (●), 0.02 mM (○), 0.1 mM (■), and 0.5 mM (□) AMP 
for the substrates Pi (a) and F6P (b).  Activities are reported in micromoles acetyl 








FIG 2.7.  AMP activates Xfp2 activity and alleviates inhibition by allosteric 
inhibitors.  Activities are reported as percentage of the maxium activity with no 
allosteric effector present.  The effectors AMP, ATP and/ or PEP were added to reactions 






ALLOSTERIC REGULATION OF LACTOBACILLUS PLANTARUM XYLULOSE 5-
PHOSPHATE/ FRUCTOSE 6-PHOSPHATE PHOSPHOKETOLASE (XFP) 
 
Katie Glenn and Kerry S. Smith 
 
I.  ABSTRACT 
 
 Xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp), which 
catalyzes the conversion of xylulose 5-phosphate (X5P) or fructose 6-phosphate (F6P) to 
acetyl phosphate, plays a key role in carbohydrate metabolism in a number of bacteria.  
Recently we demonstrated that the fungal Cryptococcus neoformans Xfp2 exhibits both 
substrate cooperativity for all substrates (X5P, F6P and Pi) and allosteric regulation in the 
form of inhibition by phosphoenolpyruvate (PEP), oxaloacetic acid (OAA) and ATP and 
activation by AMP.  Allosteric regulation has not previously been reported for the 
characterized bacterial Xfps.  Here we report the discovery of substrate cooperativity and 
allosteric regulation among bacterial Xfps, specifically the Lactobacillus plantarum Xfp.  
L. plantarum Xfp was found to be an allosteric enzyme inhibited by PEP, OAA and 
glyoxylate but unaffected by the presence of ATP or AMP.  Glyoxylate was also found to 
be an additional inhibitor to those previously reported for C. neoformans Xfp2.  As with 
71 
 
C. neoformans Xfp2, PEP and OAA share the same or possess overlapping sites on L. 
plantarum Xfp. Glyoxylate, which had the lowest half maximal inhibitory concentration 
of the three inhibitors, binds at a separate site. This study demonstrates that substrate 
cooperativity and allosteric regulation may be common properties among bacterial and 





II.  INTRODUCTION 
 
  Xylulose 5-phosphate (X5P)/ fructose 6-phosphate (F6P) phosphoketolase (Xfp), 
a member of the thiamine pyrophosphate (TPP) dependent enzyme family, catalyzes the 
production of acetyl phosphate from the breakdown of xylulose 5-phosphate (equation 
1a; EC 4.1.2.9) or fructose 6-phosphate (equation 1b; EC 4.1.2.22).  In lactic acid 
bacteria and bifidobacteria, Xfp partners with eithr acetate kinase (Ack) to generate 
acetate and ATP (equation 2) or phosphotransacetylas  (Pta) to generate acetyl-CoA and 
Pi (equation 3) (1,2).  Xfp open reading frames (ORFs) have more recently been 
discovered in euscomycete and basidiomycete fungi as well (3).  In fungi, Xfp is believed 
to partner with Ack since all fungi that have an Ack ORF have at least one, and in some 
cases two, Xfp ORFs but lack Pta (3). 
                           X5P + Pi ↔ Glyceraldehyde 3-phosphate + Acetyl phosphate        (1a)  
                               F6P + Pi ↔ Erythrose 4-phosphate + Acetyl phosphate          (1b) 
                                       Acetyl phosphate + ADP ↔ Acetate + ATP                              (2) 
                                     Acetyl-CoA + Pi ↔ Acetyl phosphate + CoA                            (3) 
 Xfp has been biochemically and kinetically characterized from several bacterial 
species, including Lactobacillus plantarum (referred to by Yevenes et al. as L. plantarum 
Xpk2) (2), Bifidobacterium spp. (1,4), Lactococcus lactis(5), Leuconostoc mesenteroides 
(5), and Pseudomonas aeruginosa (5),  and more recently one fungal species, 
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Cryptococcus neoformans Xfp2 (6).  The Bifidobacterium Xfp L. plantarum, L. lactis, L. 
mesenteroides, and P. aeruginosa Xfps displayed dual substrate specificity for both 
substrates X5P and F6P and followed Michaelis-Menten kinetics (1,2,4,5).  C. 
neoformans Xfp2 also displays dual substrate specificity but does not follow Michaelis-
Menten kinetics (6).  Instead, kinetic characterization of C. neoformans Xfp2 indicated 
the existence of both substrate cooperativity and allosteric regulation.  C. neoformans 
Xfp2 was found to be inhibited by ATP, phosphoenolpyruvate (PEP) and oxaloacetic 
acid (OAA) and activated by AMP (6). Substrate cooperativity and allosteric regulation 
have not been reported for any characterized bacteri l Xfp (1,2,4,5).   
 In this paper we describe the characterization of L. plantarum Xfp in which 
kinetic parameters were determined using the Hill equation and the influence of potential 
allosteric effectors on L. plantarum Xfp activity was examined.  L. plantarum Xfp was 
found to be an allosteric enzyme inhibited by PEP and OAA but unaffected by the 
presence of AMP or ATP.  Additionally, glyoxylate was discovered to be an inhibitor of 




III.  MATERIALS AND METHODS 
 
Materials 
 All chemicals were purchased from Sigma Aldrich, VWR, Fisher Scientific, or 
Gold Biotechnology.  The recombinant plasmid pET28b-xpk2 in Escherichia coli BL21 
(DE3) was kindly provided by Dr. Perry Frey (University of Wisconsin-Madison) for 
production of recombinant L. plantarum Xfp (2).   
Production and Purification of Recombinant L. plantarum Xfp 
 BL21 (DE3) containing the recombinant plasmid pET28b-xpk2 was grown in 
Luria-Bertani (LB) medium with 25 µg/mL kanamycin at 37 °C to an absorbance of ~0.8 
at 600 nm.  Recombinant L. plantarum Xfp production was induced by the addition of 1 
mM isopropyl β-D-1-thiogalactopyranoside (IPTG).  Cells were allowed to grow 
overnight at room temperature and harvested by centrifugation.     
 Cells were suspended in buffer A (25 mM Tris, 150 mM sodium chloride, 20 mM 
imidazole, 1 mM dithiothreitol (DTT) and 10% glycerol [pH 7.4]) and lysed by two 
passages through a French pressure cell at approximately 130MPa.  Cell lysate was 
clarified by ultracentrifugation at 100,000 x g for1.5 hours.  The supernatant was applied 
to a 5 mL His-Trap HP column (GE Healthcare) and subjected to column 
chromatography using an AKTA-FPLC (GE Healthcare).  After washing with at least 
seven column volumes of buffer A to remove any unbod protein, the column was 
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subjected to a linear gradient of 20 to 500 mM imidazole to remove all column-bound 
protein.  Fractions determined to contain L. plantarum Xfp by SDS-PAGE and activity 
assays were pooled and dialyzed overnight against buffer containing 25 mM Tris, 1 mM 
DTT, and 10% glycerol [pH 7.0].  Protein concentration was determined using a modified 
Bradford assay (7) with bovine serum albumin as standard, and purified protein was 
stored at -80°C. 
Production and Purification of Recombinant C. neoformans Xfp2 
 The recombinant plasmid pET21b-XFP2 synthesized by GenScript was 
transformed into the E. coli expression strain RosettaBlue™ (Novagen).  The 
recombinant strain was grown in LB medium supplemented with 1 % dextrose, to reduce 
basal level transcription from the T7 RNA polymerase gene under the control of L8-UV5 
promoter in the DE3 prophage prior to the addition of IPTG, and 50 µg/mL ampicillin 
and 34 µg/mL chloramphenicol.  At an absorbance of ~0.8 at 600 nm, IPTG was added to 
a final concentration of 1 mM to induce production of the enzyme.  Expression was 
allowed to proceed overnight at room temperature, and cells were harvested by 
centrifugation.  Recombinant C. neoformans Xfp2 was purified as previously described 
(6).  
Xfp Assay 
Enzymatic activity was measured using the hydroxamate assay to detect the production of 
acetyl phosphate (1,2,6,8).  A standard 200 µL reaction ontained 0.5 mM thiamine 
pyrophosphate (TPP), 1 mM DTT, 5 mM magnesium chloride, and 50 mM MES (at pH 
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6.0 for L. plantarum Xfp assays and pH 5.5 for C. neoformans Xfp2 assays) with varied 
concentrations of the substrates F6P and Pi, in the form of sodium phosphate pH 6.0 for 
L. plantarum Xfp and pH 5.5 for C. neoformans Xfp2.  Reactions were initiated by the 
addition of enzyme and allowed to proceed for 30 minutes at 37°C for L. plantarum Xfp 
and 40°C for C. neoformans Xfp2.  After 30 minutes, 100 µL of 2 M hydroxylamine 
hydrochloride (pH 7.0) was added, and reactions were allowed to incubate at room 
temperature for 10 minutes to fully convert all acetyl phosphate to acetyl hydroxamate. 
Reactions were terminated by the addition of 600 µL of a 50:50 mixture of 2.5 % ferric 
chloride in 2N hydrochloric acid and 10 % trichloroacetic acid to generate the ferric-
hydroxamate complex.  The color change due to product formation was measured by a 
change in absorbance at 540 nm.  All data sets correspond to reactions performed in 
triplicate. 
L. plantarum Xfp Kinetic Analysis 
 To determine L. plantarum Xfp kinetic parameters, one substrate was varied 
while the other substrate was held constant at a saurating concentration (60 mM for F6P 
and 8 mM for Pi).  Since the commercial availability of X5P has been discontinued, all 
kinetic parameters were determined using F6P.  Dataw s plotted using KaleidaGraph 
software (Synergy), and kinetic parameters were found by applying the Hill equation 
(equation 4) (9,10) to the data set where V0 is initial velocity, [S] is substrate 
concentration, V is maximum velocity, K0.5 is substrate concentration at half maximal 
velocity and h is the Hill constant.        
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                                         (4) 
Determination of Inhibitor IC50 Values (Individually and in Combination)  
 The half maximal inhibitory concentration (IC50) was determined for each L.
plantarum Xfp inhibitor and an additional C. neoformans Xfp2 inhibitor not previously 
described by measuring the decrease in enzyme activity at K0.5 substrate concentrations 
(11 mM F6P and 1 mM Pi for L. plantarum Xfp and 16 mM F6P and 13 mM Pi for C. 
neoformans Xfp2) in the presence of increasing inhibitor conce tration.  The IC50 was 
found by fitting the data with a log [inhibitor] vs response curve in Graphpad Prism 5 
software.  In order to determine if inhibitors share the same or overlapping allosteric 




IV.  RESULTS 
 
Effect of pH on L. plantarum Xfp Activity 
 Recombinant L. plantarum Xfp was produced and purified using nickel affinity 
chromatography.  It was previously discovered that C. neoformans Xfp2 activity is 
significantly reduced with increasing pH and that maximal activity occurs between pH 
4.5 and 6.0 (6).  Like C. neoformans Xfp2, L. plantarum Xfp activity decreases with 
increasing pH. However, the decrease in activity does not occur until pH 6.5 versus pH 
6.0 for C. neoformans Xfp2 (Fig. 1) suggesting that L. plantarum Xfp is slightly more 
tolerant to elevated pH than C. neoformans Xfp2.  Maximum L. plantarum Xfp activity 
occurs around pH 6.0 which was used in all kinetic assays.   
Kinetic Characterization of L. plantarum Xfp 
 We have recently shown that C. neoformans Xfp2 displays substrate cooperativity 
and is subject to allosteric regulation (6), neither of which have been reported for any of 
the bacterial Xfp enzymes (1,4,5,11), including the L. plantarum Xfp (2). To establish 
whether substrate cooperativity exists for L. plantarum Xfp, apparent kinetic parameters 
(Table 1) were determined in the acetyl phosphate forming direction for the substrates 
F6P and Pi by fitting the Hill equation to plots of substrate concentration versus velocity. 
L. plantarum Xfp displays negative cooperativity for Pi as indicated by a Hill constant of 
0.68 ± 0.02, similar to the Hill constant of 0.59 ± 0.03 for the C. neoformans enzyme (6). 
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The K0.5 value of 1.0 ± 0.1 mM for Pi is similar to the Km previously determined for the L.
plantarum enzyme (2).   
 Unlike C. neoformans Xfp2, L. plantarum Xfp Hill constant of approximately 1.0 
does not indicate the existence of substrate cooperativity in regards to F6P binding.  F6P 
progress curves for L. plantarum Xfp were found to fit both the Michaelis-Menten and 
Hill equations equally well with R values around 0.99.  Using the Michaelis-Menten 
equation Km
app for F6P was determined to be 10.8 ± 0.8 mM, while a K0.5 for F6P of 11.0 
± 1.4 mM was calculated using the Hill equation for the same data set.  Both F6P K0.5 and 
Km
app are on the same order of magnitude as the Km
app for F6P previously determined by 
Yevenes et al. (2).   
L. plantarum Xfp is Inhibited by PEP and OAA, but Unaffected by AMP and ATP.  
 The same ligands examined as possible allosteric effe tors of C. neoformans Xfp2 
(6) were tested to determine their effect on L. plantarum Xfp activity.  As with C. 
neoformans Xfp2, L. plantarum Xfp is inhibited by phosphoenolpyruvate (PEP) and 
oxaloacetic acid (OAA) (Fig. 2) and slightly inhibited by citrate (data not shown).  L
plantarum Xfp activity was unaffected by the presence of AMP or ATP, the primary 
allosteric activator and inhibitor, respectively, of C. neoformans Xfp2.  Additional 
ligands tested such as acetate and pyruvic acid that had no effect on C. neoformans Xfp2 




Glyoxylate Inhibits both L. plantarum Xfp and C. neoformans Xfp2 Activity 
 Since PEP and OAA serve as common allosteric effectors for bacterial L. 
plantarum Xfp and eukaryotic C. neoformans Xfp2, various PEP analogs were tested to 
determine the specificity of this allosteric site for PEP and the primary chemical moiety 
that contributes to the allosteric inhibitory effect.  Non-phosphorylated PEP analogs have 
previously been utilized to determine the chemical moiety that contributes to allostery in 
muscle pyruvate kinase (12), and each of these PEP analogs were used to test L. 
plantarum Xfp inhibition (Fig. 3a).  Interestingly, glyoxylate was found to inhibit Xfp in 
addition to PEP and OAA.  L. plantarum Xfp was almost fully inhibited by 8 mM 
glyoxylate with only 7.2 ± 1.0% activity remaining but only partially inhibited by 8 mM 
PEP (45.7 ± 3.4% activity remaining).  Pyruvate showed no inhibition while the PEP 
analogs D-lactate, L-lactate, methyl pyruvate, hydroxyacetone, and glycolate displayed 
intermediate levels of inhibition.  These same PEP analogs were used to test their 
inhibitory effect against C. neoformans Xfp2 as well, and the results were similar to those 
found for the L. plantarum Xfp.  Glyoxylate also inhibits C. neoformans Xfp2 activity, 
with 8 mM reducing activity to 15.3 ± 1.0%.  Similar to L. plantarum Xfp, pyruvate had 
no effect on C. neoformans Xfp2 activity while all other PEP analogs show intermediate 





Determination of Allosteric Effector Half Maximal Inhibitory Concentrations 
(IC50s) 
 The IC50 half maximal inhibitory concentration was determined for each L. 
plantarum Xfp inhibitor (Table 2) using K0.5 substrate concentrations.  The IC50 for 
glyoxylate was lower than those for PEP and OAA by approximately 3-fold and 5-fold, 
respectively. In order to determine if any of these inhibitors share the same site, the IC50 
of one inhibitor was determined in the presence of a second inhibitor held constant at its 
IC50.  If two inhibitors share the same site or if their sites overlap, then approximately 
half the sites should be occupied by the inhibitor held constant thereby lowering the 
amount of the varied inhibitor required to reduce ativity by an additional 50%.   
 In the presence of 10.5 mM OAA, the PEP IC50 decreased more than half the 
original value, demonstrating that the L. plantarum PEP and OAA binding sites are the 
same or overlapping, as indicted previously for C. neoformans Xfp2 (6).  The reason the 
IC50 of PEP is reduced by more than half in the presence of OAA is most likely due to the 
unique inhibitory effect of OAA (Fig 4a) not seen in glyoxylate (Fig 4b) or PEP (Fig 4c) 
inhibition profiles.  High concentrations of OAA were required to initiate L. plantarum 
Xfp inhibition followed by a sharp decrease in activity in the presence of additional OAA 
(Fig 4a).  This inhibitory concentration threshold may suggest that PEP and OAA interact 
with the binding site differently or that these areoverlapping instead of identical binding 
sites.  The IC50 of PEP does not change significantly in the presence of 2 mM glyoxylate 
while the IC50 of OAA decreases by approximately 26%.  Therefore, it appears that the 
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PEP/OAA site is separate from the glyoxylate site since neither PEP nor OAA IC50 
display close to a 50% decrease in the presence of 2 mM glyoxylate.   
 Since glyoxylate was not previously recognized as an Xfp inhibitor (6), the IC50 
of glyoxylate was determined for C. neoformans Xfp2 (Table 2).  The C. neoformans 
Xfp2 PEP IC50 of 5.31 ± 0.13 mM, slightly lower than the 8 mM IC50 previously 
reported, (6) decreased to 4.01 ± 0.07 mM in the presence of 5 mM glyoxylate.  Since the 
IC50 of PEP only decreases by about 24% in the presence of 5 mM glyoxylate, it is likely 
that the binding of PEP and glyoxylate occur at separate sites on C. neoformans Xfp2 as 
well.   
Allosteric Inhibitors Influence F6P Binding 
 Progress curves of substrate concentration versus activity were generated for L. 
plantarum Xfp substrates F6P and Pi in the presence of increasing PEP concentrations 
(Fig. 5).  The presence of PEP had the same effect on L. plantarum Xfp kinetic 
parameters as it did for C. neoformans Xfp2 (6).  In regards to Pi, the presence of PEP 
had little effect on K0.5, which remained between 1.0 ± 0.03 mM and 1.3 ± 0.30 mM at 0 
mM PEP and 16 mM PEP respectively, or Hill constant, which ranged between 0.66 ± 
0.01 and 0.49 ± 0.02. However, a gradual reduction in Vmax from 1.06 ± 0.01 µmol of 
product formed per 30 minute reaction at 0 mM PEP to 0.80 ± 0.04 µmol at 16 mM PEP 
was observed.  The K0.5 of F6P increased from 9.8 ± 0.2 mM in the absence of inhibitor 
to 37.8 ± 0.9 mM in the presence of 16 mM F6P and the Hill constant also increased from 
1.31 ± 0.01 to 1.79 ± 0.01.  The presence of PEP had little effect on F6P maximal activity 
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with Vmax ranging between 0.93 ± 0.02 and 0.87 ± 0.01 µmol of product formed per 30 
minute reaction.  Since PEP and OAA bind at the same or overlapping sites on L.
plantarum Xfp, PEP was utilized to represent the effect of both PEP and OAA inhibition 
on substrate binding.  The influence that PEP inhibtion has on the F6P K0.5 and Hill 
constant suggests that, similar to C. neoformans Xfp2 (6), the binding of PEP and OAA 
directly influences the binding of F6P to the L. plantarum Xfp active site. Glyoxylate 
binding did not significantly influence F6P K0.5 but had a greater influence on Vmax (data 
not shown).   
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V.  DISCUSSION 
 
 Recently we determined that a fungal Xfp, C. neoformans Xfp2, displayed both 
substrate cooperativity (positive cooperativity for F6P and negative cooperativity for Pi)
and allosteric regulation in the form of inhibition through the binding of ATP, PEP and 
OAA and activation by the binding of AMP (6).  Here w  report the discovery of 
substrate cooperativity and allosteric regulation fr bacterial L. plantarum Xfp.  This 
report describes the first indication that substrate cooperativity and allosteric regulation 
also exists among at least some bacterial Xfp enzymes.  Kinetic parameters for L.
plantarum Xfp were originally determined by Yevenes et al. by fitting substrate progress 
curves with the Michaelis-Menten equation to determine apparent binding constants Km
for F6P and Pi which were found to be 24 ± 4 mM and 2.9 ± 0.5 mM respectively (2).  
We produced the recombinant L. plantarum Xfp and demonstrated that this enzyme 
displays negative cooperativity in regards to Pi binding with a Hill constant less than one 
but little cooperativity in regards to F6P binding with a Hill constant roughly equal to 
one.   
 In addition to substrate cooperativity, L. plantarum Xfp, like C. neoformans Xfp2, 
is allosterically regulated.  It is inhibited by PE and OAA, but unlike C. neoforamans 
Xfp2 the presence of ATP or AMP had little to no effect on activity.  Initially L. 
plantarum Xfp kinetic parameters did not suggest the presence of substrate cooperativity 
for F6P binding alone however the presence of the in ib tor PEP induces positive 
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cooperativity as demonstrated by the sigmoidal progress curves and increase in F6P Hill 
constant shown in Fig. 5.  Unlike PEP, glyoxylate inhibits enzyme activity without 
greatly influencing F6P binding since both F6P Km and Hill constant were not greatly 
altered.  In regards to C. neoformans Xfp2 and L. plantarum Xfp regulation by excess 
PEP and OAA, the presence of these intermediates indicate the energy needs of the cell 
have been met.  The cell can switch from glycolysis, the breakdown of glucose, to 
gluconeogenesis to synthesize and ultimately store glucose until it is needed, and 
therefore, Xfp may be inhibited by these intermediates in order to limit additional energy 
production through the Xfp/Ack pathway (6).   
 In addition to Xfp, L. plantarum can produce acetyl phosphate from pyruvate 
using pyruvate oxidase (Pox) and from acetyl-CoA using phosphotransacetylase (Pta).  It 
has been shown that at least some Acks in heterofermentative bacteria are allosterically 
regulated (13).  Perhaps Xfp regulation by the presence of ATP and AMP is less 
necessary in L. plantarum that has additional sources for acetyl phosphate production and 
may also possess an allosterically regulated Ack, though this has not been experimentally 
proven.  Xfp regulation by ATP and AMP may have evolved in C. neoformans where 
there is no evidence of an allosterically regulated Ack (C. Ingram-Smith, A. Guggisberg, 
S. Henry, J. Welch, K. Laws, A. Mattison, A. Bizhanova, and K. Smith, manuscript in 
preparation) or the presence of additional acetyl phos hate producing enzymes such as 
Pox and Pta.  Therefore, the control of ATP production by Ack in C. neoformans may 
rest solely on the production of acetyl phosphate by Xfp. 
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 Non-phosphorylated PEP analogs were tested to determin  the primary chemical 
moiety that contributes to PEP allosteric inhibition f r both L. plantarum Xfp and C. 
neoformans Xfp2.   Interestingly, pyruvate displayed no inhibition while glyoxylate, 
which differs from pyruvate by the absence of a single methyl group, inhibits L. 
plantarum Xfp more than PEP or OAA at the same concentration.  Our results suggest 
that PEP and OAA bind to the same or overlapping sites in both L. plantarum Xfp and C. 
neoformans Xfp2, but glyoxylate binds at a distinct site. 
 Since glyoxylate is an allosteric inhibitor with presumably its own allosteric site 
on both L. plantarum Xfp and C. neoformans Xfp2, there is likely a metabolic connection 
between the presence of excess glyoxylate and the inhibition of Xfp, consequently 
limiting the production of acetyl phosphate from X5P and F6P.  The glyoxylate cycle 
functions as a bypass of the decarboxylation steps of the tricarboxylic acid cycle allowing 
for the use of simple two-carbon compounds, such as acetate and ethanol, to generate 
malate from the combined action of the enzymes isocitrate lyase (Icl) and malate 
synthase (Mls) (14-16).  The glyoxylate cycle is utilized when glucose is limiting (14), 
but the production of excess glyoxylate may indicate that other 2-carbon compounds, 
such as acetate, are prevalent. Since we hypothesize that C. neoformans Xfp2 partners 
with Ack to generate acetate and ATP, the presence of excess glyoxylate may indicate 
that acetate is in abundance, so glyoxylate inhibits Xfp thereby inhibiting the production 
of acetyl phosphate and consequently the production of acetate by Ack.   
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 We have failed to identify genes encoding the enzymes Icl and Mls within the L. 
plantarum genome suggesting it lacks a glyoxylate cycle.  However, L. plantarum cell 
free extract is capable of metabolizing glyoxylate (17).  An ORF within the L. plantarum 
genome designated as 2-hydroxyacid dehydrogenase (Acc ssion # YP_004888759) has 
61% identity to a gene designated as a glyoxylate reductase (equation 5) in Lactobacillus 
otakiensis, and it has also been shown in Rhizobium etli that an enzyme previously 
labeled as 2-hydroxyacid dehydrogenase displays glyoxy ate reductase activity (18).  
                                 glyoxylate + NAD(P)H ↔ glycolate + NAD(P)+                            (5) 
In plants, glyoxylate reductase is believed to function as a way of removing excess 
reducing equivalents like NADPH (19), and glyoxylate reductase in L. plantarum could 
serve a similar purpose.  A possible connection betwe n L. plantarum Xfp inhibition by 
excess glyoxylate is that the presence of glyoxylate could indicate the presence of excess 
NADPH.  The pentose phosphate pathway (PPP) serves as a major source of the NADPH 
produced in the cell. Thus, inhibiting Xfp, which utilizes PPP end products, may hinder 
the PPP from producing additional end products thereby also reducing the amount of 
NADPH produced upstream.  The regulation of Xfp by glyoxylate in L. plantarum may 
serve as a means of balancing the production and utilization of NADPH by the PPP and 





Concluding Remarks  
 Substrate cooperativity and allosteric regulation ca no longer be considered a 
purely eukaryotic Xfp phenomenon with the discovery of its existence in at least some 
bacterial Xfps, specifically L. plantarum Xfp.    However, there are differences between 
the degree of substrate cooperativity and the allosteric effectors that inhibit or activate 
eukaryotic Xfp and bacterial Xfp from C. neoformans and L. plantarum respectively.  
Both C. neoformans Xfp2 and L. plantarum Xfp share PEP, OAA and glyoxylate as 
allosteric inhibitors, but C. neoformans Xfp2 is also inhibited by ATP and activated by 
AMP while an activator of L. plantarum Xfp has yet to be discovered.  Tighter regulation 
of Xfp by ATP:AMP ratios may have evolved for eukaryotic Xfps due to the lack of 
additional partner enzymes, compared to bacteria, that generate acetyl phosphate as a 
substrate for Ack.  Additionally, regulation by glyoxylate appears to result from different 
phenomenon in C. neoformans that primarily produces glyoxylate through the glyox late 
cycle versus L. plantarum which appears to lack a glyoxylate cycle.  The presence of 
allosteric regulation for both bacterial and eukaryotic Xfps suggests the production and 
utilization of acetyl phosphate is important under ifferent environmental stresses that 
ultimately influence cellular metabolism.  
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TABLE 3.1.  Apparent kinetic parameters for L. plantarum Xfp and C. neoformans 
Xfp2. 
 



















F6P 11.0 ± 1.4 1.05 ± 0.05 0.10 ± 0.01 0.99 ± 0.04 
P
i
 1.0 ± 0.1 1.12 ± 0.03 1.11 ± 0.09 0.68 ± 0.02 
C. neoformans 
Xfp2*  
F6P 15.9 ± 1.3 3.47 ± 0.10 0.22 ± 0.01 1.41 ± 0.11 
P
i
 13.3 ± 1.5 4.22 ± 0.13 0.32 ± 0.03 0.59 ± 0.03 






TABLE 3.2.  Half maximal inhibitory concentrations (IC50s)  
 
 Enzyme  Inhibitor (Varied) Inhibitor (Constant) IC50 (mM) 
L. plantarum 
Xfp 
Glyoxylate -------- 1.93 ± 0.05 
PEP 
-------- 6.70 ± 0.12 
OAA (10.5 mM) 1.14 ± 0.12 
Glyoxylate (2 mM) 6.04 ± 0.11 
OAA 
-------- 10.5 ± 0.07 




-------- 4.93 ± 0.04 
PEP (8 mM) 3.13 ± 0.18 
PEP 
-------- 5.31 ± 0.13 







FIG 3.1.  Effect of pH on L. plantarum Xfp and C. neoformans Xfp2 percent activity.  
Enzyme reactions were performed using F6P and Pi K0.5 concentrations for L. plantarum 
Xfp (■) and C. neoformans Xfp2 (●).  Activity begins to decrease at pH values above 6.0 







FIG 3.2.  Effect of various ligands on L. plantarum Xfp activity.  Reactions were 
performed using L. plantarum Xfp F6P and Pi K0.5 substrate concentrations.  Two 
concentrations of each coenzyme or metabolic intermediate were tested.  Reactions were 





FIG. 3.3.  Effect of non-phosphorylated PEP analogs on 
neoformans Xfp2 (B) activity.
and Pi K0.5 substrate concentrations.  Concentrations of 8 mM (dark grey) and 16 mM 
(light grey) for each non-phosphorylated PEP analog were tested in triplicate.  Activity is 








 (A) and C. 
 Xfp F6P 
 
FIG 3.4.  Inhibition of L. plantarum Xfp by OAA, PEP and glyoxylate.
were performed in triplicate using 
concentrations.  Activity was measured in the presence of increasing concentrations of 
OAA (A), glyoxylate (B) or PEP (C) and reported as a percentage of maximal activity 
with no ligand presence.   
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FIG 3.5.  Effect of PEP on L. plantarum Xfp
curves were generated in the presence of 0 mM (
the substrates Pi (a) and F6P (b).
were reported as µmol of product formed.
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INVESTIGATIONS INTO THE LOCATION OF C. NEOFORMANS XFP2 
ALLOSTERIC SITES THROUGH COMPUTATIONAL MODELING                      
AND SITE-DIRECTED MUTAGENESIS 
 
Katie Glenn and Kerry Smith 
 
I.  ABSTRACT 
 
Xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp) catalyzes the 
reaction converting xylulose 5-phosphate (X5P) or fructose 6-phosphate (F6P) to acetyl 
phosphate and glyceraldehyde 3-phosphate (G3P) or erythrose 4-phosphate (E4P) 
respectively.  Recently we have determined that at least some fungal and bacterial Xfps 
are allosteric enzymes.  Both Cryptococcus neoformans Xfp2 and Lactobacillus 
plantarum Xfp are inhibited by phosphoenolpyruvate (PEP), oxaloacetic acid (OAA), and 
glyoxylate, and PEP and OAA appear to share the same or possess overlapping sites on 
both Xfps.  The C. neoformans Xfp2 is also inhibited by ATP and activated by AMP, but 
the L. plantarum enzyme is unaffected by these ligands. Additional studies provide 
evidence that ATP inhibition of C. neoformans Xfp2 may be dependent on ATP 
hydrolysis.  Currently the only crystal structures that exist of Xfp are from two bacteria, 
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Bifidobacterium breve and Bifidobacterium longum.  Here we describe the generation of 
both a monomer and dimer model of C. neoformans Xfp2 using the existing bacterial Xfp 
crystal structures.  The models were used to identify possible allosteric binding sites, and 
ligand docking simulations were performed using PEP and OAA in an attempt to 
discover the location of the PEP/OAA allosteric site.  Residues predicted to form 
hydrogen bonds with PEP and OAA were altered to the neutral residue alanine or amino 
acids of opposite charge, but these alterations have yet to define the PEP/OAA pocket(s). 
Also we discovered that AMP functions as a very potent enzyme activator capable of 
rescuing activity of enzyme variants displaying much lower activity than wild type. 
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II.  INTRODUCTION 
 
  Xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp) is a thiamine 
pyrophosphate (TPP) dependent enzyme that catalyzes the conversion of xylulose 5-
phosphate (X5P, EC 4.1.2.9; X5P + Pi → acetyl phosphate + glyceraldehyde 3-
phosphate) or fructose 6-phosphate (F6P, EC 4.1.2.22; F6P + Pi → acetyl phosphate + 
erythrose 4-phosphate) to acetyl phosphate.  Originally identified and characterized in 
bacteria (1-4), Xfp has more recently been found in euascomycete and basidiomycete 
fungi as well (5).  Phylogenetic analysis show thatfungal Xfps separate into two distinct 
clades designated as XFP1 and XFP2 (A. Guggisberg and K. Smith, unpublished data). 
All fungi in which an acetate kinase (ACK) open reading frame (ORF) has been identified 
also have an XFP ORF (5).  Therefore, as in certain bacteria, Xfp is believed to partner 
with Ack (EC 2.7.2.1; acetyl phosphate + ADP ↔ acetate + ATP) in fungi as part of a 
modified pentose phosphate pathway to generate acetate and ATP from pentose 
phosphate pathway product X5P and F6P via formation of acetyl phosphate.  
 We purified and characterized the first eukaryotic Xfp, Cryptococcus neoformans 
Xfp2 (Accession # CNAG_06923.7) (6).  Unlike previously characterized bacterial Xfp 
enzymes (1-4), C. neoformans Xfp2 displayed both substrate cooperativity (positive 
cooperativity in regards to F6P binding and negative cooperativity for Pi binding) and 
allosteric regulation.  C. neoformans Xfp2 activity was  inhibited by ATP, 
phosphenolpyruvate (PEP), oxaloacetic acid (OAA), (6) and glyoxylate (K. Glenn and K. 
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Smith, in revision) and activated by AMP (6).  Previous kinetic characterizations of Xfp 
from bacteria do not report the presence of either substrate cooperativity or allosteric 
regulation for these enzymes (1-4).  Recently, we purified and demonstrated that the 
Lactobacillus plantarum Xfp, initially characterized by Yevenes t al. (2), displayed both 
substrate cooperativity and allosteric regulation.   We found that L. plantarum Xfp is an 
allosteric enzyme inhibited by PEP, OAA and glyoxylate but unaffected by ATP and 
AMP; and this enzyme also exhibits negative cooperativity for Pi (K. Glenn and K. 
Smith, in revision).   
 Currently, the structures of Bifidobacterium breve (3) and Bifidobacterium 
longum (7) Xfp enzymes have been solved.  Analysis of these structures show that the 
Xfp monomer consists of 3 domains, the N-terminal (PP) domain, the Middle (Pyr) 
domain and the C-terminal domain, with the active st  located between the PP and Pyr 
domains (3,7).  Both structures support the ping pong bi bi reaction mechanism originally 
proposed by Yevenes et al. (2,3,7).  Even though neither B. breve nor B. longum Xfp 
have been reported to be allosterically regulated, our studies have shown that at least one 
bacterial Xfp, L. plantarum Xfp, is an allosteric enzyme (K. Glenn and K. Smith, n 
revision).  Here we describe the generation of a C. neoformans Xfp2 model from the 
existing B. breve and B. longum Xfp crystal structures.  Since both a bacterial Xfp and C. 
neoformans Xfp are allosterically regulated by PEP and OAA at a shared or overlapping 
site (K. Glenn and K. Smith, in revision), we performed ligand docking simulations to 
attempt to determine the location of C. neoformans Xfp2 allosteric binding sites, 
primarily focusing on the PEP/OAA binding site.  
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III.  MATERIALS AND METHODS 
 
Materials 
 All chemicals were purchased from VWR, Fisher Scientific, or Sigma Aldrich.  
Oligonucleotides for site-directed mutagenesis were purchased from Integrated DNA 
Technologies.   
Molecular Modeling 
 All modeling was performed using Accelrys Discovery Studio 3.5 software.  The 
C. neoformans Xfp2 monomer model was built from the aligned and superimposed 
template structures of both B. breve (PDB ID 3AHC) and B. longum (PDB ID 3AI7) Xfp 
downloaded from RSCB Protein Data Bank (PDB).  The C. neoformans Xfp2 homodimer 
model was built from the B. longum Xfp structure (PDB ID 3AI7).  The monomer and 
homodimer model with the lowest Discrete Optimized Protein Energy (DOPE) score 
were chosen for further analysis.  Models were prepar d prior to use by other software 
applications using the Automatic Preparation function hat prepares the protein by 
inserting missing atoms, modeling missing loops, removing water molecules and 
protonating residues based on a pH of 5.5, at which maximal C. neoformans Xfp2 
activity occurs.  Possible allosteric binding sites were determined by first identifying all 
possible cavities on the Xfp2 model using the Define a d Edit Binding Sites From 
Receptor Cavities function.  Ligand docking simulations were then performed for a 
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specified ligand using the software’s LibDOCK function that docks ligands within a site 
based on the ligand’s interaction with polar and apol r regions within that site.   
Site-Directed Mutagenesis 
 Site-directed mutagenesis was performed on the codon- ptimized C. neoformans 
Xfp2 gene using the QuikChange site-directed mutagenesis kit (Agilent Technologies, 
Inc.) to alter residues predicted to interact with ligands within proposed ligand binding 
sites of the Xfp2 model. Mutagenic primers were approximately 40 nucleotides in length 
with the altered base located in the center of the sequence.  Mutagenesis was confirmed 
by Sanger-style sequencing at the Clemson University Genomics Institute.   
Production and Purification of C. neoformans Xfp2 Variants 
Confirmed Xfp2 variants were produced in the Eschericia coli expression strain 
RosettaBlue™ (Novagen) grown in LB medium supplemented with 1 % dextrose, 50 
µg/mL ampicillin, and 34 µg/mL chloramphenicol.  Atan absorbance of ~0.8 at 600 nm, 
IPTG was added to a final concentration of 1 mM to induce production of the enzyme.  
Expression was allowed to proceed overnight at room te perature, and cells were 
harvested by centrifugation.  C. neoformans Xfp2 variants were purified as previously 
described for wild type C. neoformans Xfp2 (6). 
   Enzymatic Assays for Xfp2 Activity  
C. neoformans Xfp2 activity was determined by measuring the production of 
acetyl phosphate using a modified hydroxamate assay previously described (6,8).  200 µL 
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standard reaction mixtures were prepared as previously described (6), and only F6P and 
sodium phosphate pH 5.5 were used as substrates due to the lack of commercial 
availability of X5P.  Reactions were initiated by the addition of enzyme and allowed to 
proceed for 30 minutes at 40°C.  Afterwards, 100 µL of 2M hydroxylamine HCl (pH 7.0) 
was added to each reaction, and the reactions were allowed to incubate at room 
temperature for 10 minutes to convert all acetyl phosphate to acetyl hydroxamate.  
Finally, reactions were terminated by the addition of 600 µL of a 50:50 mixture of 2.5 % 
FeCl3 in 2N HCl and 10 % trichloroacetic acid to generate the ferric hydroxamate 
complex that was measured spectrophotometrically at 540 nm.  Most initial tests of 
variant activity in the presence and absence of both PEP and AMP were performed in 
singlet trials.  The R66A variant full kinetic analysis and all ATP hydrolysis experiments 
were performed in triplicate.   
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IV.  RESULTS 
 
Generation of C. neoformans Xfp2 monomer model 
 The C. neoformans Xfp2 monomer model (Figure 4.1) was built from the
monomer structures of both B. breve and B. longum Xfp using Accelrys Discovery Studio 
3.5 software.  Like the B. breve and B. longum Xfp, the C. neoformans Xfp2 monomer 
consists of an N-terminal PP (blue), middle Pyr (white) and C-terminal (red) domain.  
The Define Binding Site from Receptor Cavities function was performed and located a 
total of 44 possible binding sites on the C. neoformans Xfp2 model.  Ligand docking 
simulations showed that TPP binds to site 5 on the model which overlaps well with the 
TPP binding sites of B. breve (3) and B. longum Xfp (7).  Therefore, site 5 (labeled with a 
red circle in Figure 4.1) is considered to be the location of the C. neoformans Xfp2 active 
site. 
Investigations into the location of the C. neoformans Xfp2 PEP/OAA allosteric site 
based on bonds formed between ligand and evolutionarily conserved residues 
 The PEP and OAA molecule structures were imported into Discovery Studio 3.5 
software and docked into each of the 44 possible binding sites using the LibDock 
function.  Both PEP and OAA were successfully docked into many of the sites.  Since 
PEP and OAA have been demonstrated to be allosteric effe tors for the bacterial L. 
plantarum Xfp (K. Glenn and K. Smith, in revision) and the eukaryotic C. neoformans 
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Xfp2 (6), we hypothesize that this site may be evoluti narily conserved among both 
bacterial and eukaryotic Xfps.  Therefore, we attempted to narrow down the number of 
candidate PEP/OAA binding sites by focusing on sites in which both PEP and OAA can 
bind and directly interact, through hydrogen bonding, with several evolutionarily 
conserved residues within that site.  ConSurf server was used to determine if a residue is 
evolutionarily conserved  (9,10).  The ConSurf server first searches for sequences 
homologous to the sequence of interest and then uses multi-sequence alignment, existing 
structures, and phylogenetic analysis to assign residu  in the input sequence a score of 1 
to 9, with a score of 9 assigned to residues that are considered to be highly conserved.   
 Utilizing the methodology outlined above we identified two sites, site 13 and site 
35, as PEP/OAA binding site candidates.  The position of these sites on the C.
neoformans Xfp2 monomer model (Figure 4.2), along with 2D diagrams that represent 
one of several positions in which PEP can bind within each site. In both site 13 and site 
35, PEP and OAA hydrogen bond with two evolutionarily conserved residues (ConSurf 
scores of 8 or 9).  Site-directed mutagenesis was performed to generate the individual 
variants R66A and K64A in site 13 and D547K and K602A in site 35 because these 
residues had high ConSurf scores and were predicted to directly interact with PEP and 
OAA by forming hydrogen bonds.  All residues for which mutagenesis was performed 
are listed in Table 4.1 along with their ConSurf scores and binding site location.   
 The C. neoformans Xfp2 R66A variant was the only variant active enough to 
perform a full kinetic analysis (Table 4.2).  Alteration of Arg66 to Ala primarily reduced 
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the overall enzyme activity demonstrated by a much lower kcat
app compared to wild type 
(WT) C. neoformans Xfp2.  The R66A variant has similar K0.5 values to those of the WT 
and also retains both positive cooperativity (h>1) for F6P and negative cooperativity 
(h<1) for Pi (Table 4.2).  Since the R66A variant was generated due to its possible 
interactions with PEP within a proposed PEP/OAA binding site, PEP was added to the 
reaction mix to determine if activity of this variant is still inhibited by the presence of 
PEP.  All previous studies involving allosteric inhibitors have been performed using K0.5 
substrate concentrations. At K0.5 concentrations for both substrates, the activity of the 
R66A variant is only around 0.027 µmol of product formed per 30 minute reaction.  In 
the presence of 8 mM PEP, R66A activity decreases from 0.027 µmol to 0.012 µmol of 
product formed per 30 minute reaction.  Therefore, PEP still inhibits R66A activity, but it 
is difficult to compare PEP’s effect on R66A to WT C. neoformans Xfp2 at similar 
concentrations when the activity of the R66A variant is very low.   
AMP acts as a very potent enzyme activator/stabilizer 
 In an attempt to increase R66A variant activity, varying amounts of AMP, the 
only known C. neoformans Xfp2 activator (6), was added to the reaction assay.  As 
expected, like with the WT, AMP was able to increase ctivity of the R66A variant 
(Figure 4.3).  Surprisingly, the addition of AMP was ble to rescue R66A activity back to 
WT levels.  Upon the addition of 2 mM AMP, R66A activity reaches 100% WT activity 
of the same enzyme concentration.  Since AMP boosts R66A activity, PEP inhibition was 
tested in presence of AMP (Figure 4.4).  The effect of the presence and absence of 8 mM 
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PEP on R66A activity was tested on reactions containing 0.02, 0.2 and 0.5 mM AMP.  As 
shown in Figure 4.4, 8 mM PEP inhibits activity in the presence of all three 
concentrations of AMP suggesting that R66A is not ivolved in the binding of PEP.  
 To better understand why the R66A alteration drastic lly reduces enzyme activity 
and how AMP is capable of overcoming the effects of this mutation, a model was 
generated of the R66A variant using the Build Mutant fu ction of the Discovery Studio 
3.5 software.  Figure 4.5 shows an overlay of the WT C. neoformans Xfp2 model and the 
R66A variant focused on the R66 residue with a red sphere marking the active site.  The 
R66 residue is in close proximity to the active sit, and therefore, may even be involved 
in active site mechanisms such as substrate binding or stabilizing reaction intermediates.  
Additionally the R66A variant is predicted to produce several structural changes, 
indicated by green arrows in Figure 4.5, that are also in close proximity to the active site.  
Therefore the R66A model suggests that the reduction in enzyme activity may be due to 
changes in the enzyme active site but does not provide insight as to how AMP is able to 
overcome such structural alterations. 
 C. neoformans Xfp2 is known to have optimal activity at lower pH, and activity 
decreases as pH approaches neutrality.  Therefore, the ffect of AMP on C. neoformans 
Xfp2 activity in the presence of increasing pH was tested.  It was found that AMP can 
increase WT activity at K0.5 substrate concentrations at elevated pH values (Figure 4.6).  




Investigations into the location of the C. neoformans Xfp2 PEP/OAA allosteric site 
based on bonds formed between ligand and arginine residues 
 Utilizing PDBeMotif version 2.0c, an online service that searches the Protein 
Data Bank with respect to protein motifs (11), it was discovered that PEP often directly 
interacts and binds with arginine residues in protein active sites.  Therefore, all of the 
putative binding sites of the C. neoformans Xfp2 model were explored to locate sites in 
which PEP could interact with an arginine residue.  There are five sites (Figure 4.7) in 
which PEP is predicted to bind and interact with an arginine residue.  Two of these sites, 
site 10 and site 14, overlap, and PEP is predicted to interact with the same arginine 
residue, Arg571.  The four arginine residues, their ConSurf scores, the mutations 
generated, and binding site location are listed in Table 4.1.  
 Both R300A and R55A variants were active in the absence of the activator AMP 
but activity was roughly 25% lower than WT at the same concentration for R55A and 
75% lower for R300A.  Both variants displayed activation in the presence of 0.5 mM 
AMP and inhibition in the presence of 8 mM PEP.  Therefore, neither residue appears to 
be involved in PEP binding.  Purified R571A and R753A had very low concentrations (~ 
0.3 mg/mL) after column purification.  Both variants showed no activity for R753A and 
very little activity for R571A (~0.034 µmol of product formed per 30 minute reaction).  
However, the addition of 0.5 mM AMP resulted in some activity from R753A variant (~ 
0.04 µmol of product per 30 minute reaction), but this activity was inhibited by the 
addition of 8 mM PEP.  Interestingly addition of 0.5 mM AMP did not increase R571A 
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activity, but the little activity observed for this variant was inhibited by 8 mM PEP.  
Based on these findings it appears that neither R571 nor R753 are involved in PEP 
binding, however additional tests are needed to rule them out with any certainty.       
Generation of C. neoformans Xfp2 dimer structure  
 The functional unit of both B. breve and B. longum Xfp is a dimer.  However the 
only Xfp dimer structure available in PDB is that of B. longum.  Therefore, the C. 
neoformans Xfp2 dimer model (Figure 4.8) was built from the dimer structure of B. 
longum Xfp only.  The C. neoformans Xfp2 dimer model consists of two active sites still
located between the N-terminal and middle domains of each monomer.  However it has 
been shown that residues from both subunits comprise each active site of the B. longum 
Xfp (7), and this is most likely the case for C. neoformans Xfp2 as well.  Therefore, it is 
possible that allosteric sites may consist of residues from both monomers.   
ATP Inhibition may be dependent on ATP hydrolysis 
 Since the C. neoformans Xfp2 model was built from bacterial Xfps, the search for 
allosteric binding sites using this model has thus far centered on identifying the 
PEP/OAA binding sites known to exist for at least one bacterial Xfps (K. Glenn and K. 
Smith, in revision).  Therefore, the model may not be relevant in determining the location 
of the ATP or AMP site because neither of these effctors allosterically affect bacterial 
Xfp activity.  However, a non-hydrolyzable ATP analog, β,γ-methyleneadenosine 5′-
triphosphate (AMP-PCP), was used to learn more about the mechanism of ATP 
inhibition, and to determine if it is dependent on the hydrolysis of ATP.    
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 Unlike ATP, AMP-PCP does not inhibit C. neoformans Xfp2 (Figure 4.9). More 
interestingly, AMP-PCP resulted in slightly elevated activity compared to activity when 
no effector is present.  Adenosine was tested to see if inhibition is dependent on the 
adenosine portion of ATP, but adenosine alone does n t appear to contribute to 
inhibition.  These results suggest that ATP hydrolysis may be an important factor in ATP 
inhibition of C. neoformans Xfp2.  Since AMP-PCP shows slight elevation of WT 
activity, the effect of AMP-PCP at both pH 5.5 and pH 7.0 was tested to determine if 
AMP-PCP mimics AMP’s ability to enhance Xfp2 activiy at elevated pH. AMP-PCP can 
enhance WT activity at elevated pH but not to the leve  observed with AMP (Figure 
4.10).  Additionally, AMP-PCP and ATP were both adde  to the reaction to determine if 
AMP-PCP can rescue ATP inhibition.  Reactions containing both AMP-PCP and ATP 
display intermediate activity between that of ATP and AMP-PCP presence alone (Figure 
4.11) which may suggest competitive binding between both molecules to occupy the 
allosteric site.   
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V.  DISCUSSION 
 
 We have recently shown that at least some Xfp enzymes from both bacteria (K. 
Glenn and K. Smith, in revision) and fungi (6) are llosterically regulated.  Both L. 
plantarum Xfp and C. neoformans Xfp2 are inhibited by PEP, OAA and glyoxylate, and 
PEP and OAA appear to share the same or possess overlapping allosteric sites.  Here we 
attempt to locate the PEP/OAA allosteric site through ligand docking simulations using a 
C. neoformans Xfp2 model built from known bacterial Xfp crystal structures from B. 
breve (3) and B. longum (7).  Like with B. breve and B. longum Xfp, the C. neoformans 
Xfp2 model shows the active site to be located betwe n the N-terminal (PP) domain and 
the middle (PYR) domain.  The software’s Define andEdit Binding Site feature located a 
total of 44 possible binding sites on the Xfp2 model.  Sites were narrowed down using 
two different methodologies.  The first method involved focusing on sites in which both 
PEP and OAA docked and formed bonds with residues de med to be evolutionarily 
conserved due to their high ConSurf scores (9,10).  The second method involved focusing 
on sites in which docked PEP interacted with arginine residues, as a search of the 
PDBeMotif database (11) showed that PEP often forms bonds with arginine residues 
within active sites.  
Two possible PEP/OAA binding sites, site 13 and site 35 were first chosen due to 
their ability to potentially bind both PEP and OAA such that bonds were formed between 
the ligand and Xfp2 residues having high ConSurf scores.  Except for the R66A variant, 
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most of the Xfp2 variants purified were not highly concentrated, so a full kinetic analysis 
was performed only on the R66A variant.  The R66A alter tion primarily caused a 
dramatic decrease in turnover number, kcat compared to WT Xfp2.  AMP was added to 
the R66A reaction mix in an attempt to boost activity for PEP inhibition analysis, but 
surprisingly, AMP at a concentration of 2 mM was capable of rescuing R66A activity up 
to WT values (Figure 4.3).  The R66 residue is located very close to the Xfp2 active site 
(Figure 4.5).  Therefore, it is possible that R66 may play a role in active site reaction 
mechanism.  In fact generating the R66A alteration usi g the Build Mutant Function of 
Discovery Studio 3.5 software shows some structural alterations in regions of the protein 
located close to the active site (Figure 4.5).  However it remains unclear as to how AMP 
is able to override the structural changes induced by the R66A alteration.  We 
hypothesize that the binding of AMP stabilizes the active R state form of the enzyme 
over the less active T state form.  It is possible that if R66A variant destabilizes the active 
site then AMP’s ability to induce the R state may be why AMP can completely override 
this amino acid change.  In addition to being capable of circumventing enzyme alterations 
induced by amino acid changes, AMP is capable of drastically increasing C. neoformans 
Xfp2 activity at elevated pH.  The ability of AMP to induce a conformational change that 
overrides the changes caused by a residue alteration or elevated pH shows that AMP is a 
much stronger activator than previously thought.  However as the R66A variant is still 
inhibited by PEP even in the presence of AMP, this residue does not appear to be 
involved in PEP binding.  Additionally the K602A vari nt from site 35 displayed some 
activity in the presence of AMP that was also inhibited by the presence of PEP.  
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Therefore, we found no evidence suggesting either sit  13 or sites 35 as part of a 
PEP/OAA binding site. 
We vitalized a second approach to identify the PEP/OAA binding site by focusing 
on sites in which PEP forms hydrogen bonds with the sid  chain of arginine residues.  A 
search of the Protein Data Bank using PDBeMotif revealed that PEP often forms bonds 
with arginine residues within active sites.  Therefo , all arginine residues predicted to 
interact with PEP through ligand docking simulations were altered.  All four arginine 
variants displayed reduced enzyme activity; however, th  activity was still inhibited by 
the presence of PEP suggesting that these residues are not essential for PEP binding.  
Additionally three of the four variants were activaed by AMP; however, there was no 
increase in R571A variant activity in the presence of AMP.  Therefore, it is possible that 
R571A may be involved in AMP binding. The R571 residue on the C. neoformans Xfp2 
dimer model (Figure 4.12) is not near the active sit s nor is it located near junctions 
between both monomers to form the dimer suggesting it s not involved in either the 
active site mechanism or in subunit oligomerization.  The location of R571 on the C-
terminal domain lends support to a possible involvement in allosteric effector binding 
since it has been suggested that the C-terminal domain of the phosphoketolase related 
enzyme transketolase may serve as a binding site for r gulatory molecules (12).  For now 
it is difficult to determine the role that R571 plays in the Xfp2 structure because activity 
and concentration of the R571A variant were very low.  Future studies involving this 
variant will be dependent on the purification of additional, more concentrated enzyme.  
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There is no evidence that C. neoformans Xfp2 inhibition by ATP is dependent 
upon ATP hydrolysis based on the absence of a Walker motif (13) within the Xfp2 
sequence.  However, the effects of non-hydrolyzable ATP on Xfp2 activity were still 
investigated.  The presence of the non-hydrolyzable ATP analog, AMP-PCP, did not 
inhibit C. neformans Xfp2 activity and actually resulted in slightly elevated activity 
compared to the absence of any effector.  This result suggests that ATP inhibition is 
dependent upon ATP hydrolysis.  Alternatively, AMP-PCP may actually mimic the 
binding of AMP rather than ATP, which would explain the slight increase in activity 
compared to activity in the absence of effector.  Since AMP is capable of increasing C.
neoformans Xfp2 activity at elevated pH, the effect of AMP-PC on Xfp2 activity was 
tested at both pH 5.5 and pH 7.0.  AMP-PCP stimulated Xfp2 activity but the stimulation 
was much lower than that of AMP, especially at pH 7.0.  When both AMP-PCP and ATP 
are present, activity is intermediate to that of ATP or AMP-PCP present alone, suggesting 
that ATP and AMP-PCP do compete for the same allosteric site.  Additional studies are 
required to determine if ATP inhibition is truly dep ndent on ATP hydrolysis.    
In conclusion, the sites we identified in the C. neoformans Xfp2 monomer model 
proved not to be the PEP/OAA binding site.  However, other potential allosteric sites 
remain to be explored.  Phosphofructokinase (Pfk), the principle regulatory enzyme of 
glycolysis, is one of the most well studied allosteric nzymes (14).  The primary allosteric 
effectors of Pfk are ADP, which functions as an activ tor, and PEP, which functions as an 
inhibitor.   Structural studies of Pfk from B. stearothermophilus how that PEP and ADP 
both bind at a single site located at the interface between tetrameric subunits but  induce 
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very different conformational changes (14,15).  Therefore, it may be worthwhile to 
continue the search for C. neoformans Xfp2 allosteric effector sites using the dimer 
model, focusing on sites between subunits.  We haverec ntly shown that the bacterial 
Xfp from L. plantarum is not regulated by ATP and AMP, the primary inhibitor and 
activator of C. neoformans Xfp2 respectively (K. Glenn and K. Smith, in revision).  Since 
the C. neoformans Xfp2 model was built from bacterial Xfp structures, this model is less 
likely to be relevant in identifying the binding sites of AMP and ATP.  However, initial 
ligand docking simulations showed that ATP can bind in only a few predicted sites on the 
C. neoformans Xfp2 monomer, but additional binding sites will likely be revealed 
through ligand docking simulations with the dimer model.  Our preliminary studies 
suggest that ATP inhibition may even be dependent upon ATP hydrolysis as C. 
neoformans Xfp2 is not inhibited by the non-hydrolyzable ATP analog AMP-PCP.  
AMP-PCP instead caused slight enzyme activation, suggesting that AMP-PCP may 
mimic AMP binding. However, we also saw evidence consistent with competitive 
binding between ATP and AMP-PCP for the ATP allosteric site (Figure 4.11).  The 
AMP-PCP binding data also supports the idea of a single binding site for AMP and ATP, 
much like the ADP/PEP effector site of Pfk.  Continued studies of the C. neoformans 
Xfp2 monomer and dimer models should reveal more information regarding the 
mechanisms of Xfp allosteric regulation and the location of these allosteric binding sites. 
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TABLE 4.1.  C. neoformans Xfp2 enzyme variants. 
Residue ConSurf score Variant Binding Site 
R66 8, e, f R66A 13 
K64 9, e, f K64A 13 
D547 9, e, f D547K 35 
K602 9, e, f K602A 35 
R571 9, b, s R571A 10 & 14 
R753 9, e, f R753A 30 
R55 2, e R55A 17 
R300 8, e, f R300A 24 
ConSurf assigns scores1-9 with 9 corresponding to a highly conserved residue along with 





TABLE 4.2.  Apparent kinetic parameters for C. neoformans Xfp2 R66A variant 
 



















F6P 26.7 ± 1.0 0.063 ± 0.003 0.0024 ± 0.0001 2.14 ± 0.27 
P
i
 17.1 ± 2.6 0.055 ± 0.005 0.0032 ± 0.0003 0.75 ± 0.05 
C. neoformans 
Xfp2 WT* 
F6P 15.9 ± 1.3 3.47 ± 0.10 0.22 ± 0.01 1.41 ± 0.11 
P
i
 13.3 ± 1.5 4.22 ± 0.13 0.32 ± 0.03 0.59 ± 0.03 






FIG 4.1.  Model of C. neoformans Xfp2 monomer.  Model was generated using both 
the B. breve and B. longum Xfp crystal structures.  Model colored from N-terminal (blue) 
to C-terminal (red).  Active site (area where TPP binds) is marked by a transparent red 
sphere.   
  
 
FIG 4.2.  Location of the predicted
the location of sites 13, 35 and the active site on the 
model.  2D diagrams depict one of several possible poses PEP can take in each site.  
Hydrogen bonds between PEP 
with amino acid main chain) and blue (hydrogen bond with amino acid side chain) arrows 
that point towards the electron donor.  
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 PEP binding sites 13 and 35.  Red spheres mark 
C. neoformans Xfp2 monomer 








FIG 4.3.  AMP activation of C. neoformans Xfp2 R66A variant.  Reactions were 
performed in triplicate for C. neoformans Xfp2 R66A variant using WT C. neoformans 
Xfp2 F6P and Pi K0.5 concentrations in the presence of increasing amounts of AMP.  
Activity was measured as a percentage of WT C. neoformans Xfp2 where activity with 




FIG 4.4.  Effect of PEP on C. neoformans
of AMP.  Reactions were performed in singlet using wild type 




 Xfp2 R66A variant activity in the presence 
C. neoformans
µmols of product formed per 30 minute 
 
 
 Xfp2 K0.5 
 
 
FIG 4.5.  Model predicting 
neoformans Xfp2 model is in blue, and the R66A mutation model is in pink.  R66 residue 
is shown in yellow.  The C. neoformans




structural effects of R66A mutation.  The wild type 






FIG 4.6.  Effect of pH on WT
absence of AMP.  Reactions were performed in triplicate using K
concentrations, and activity is reported as 
reaction.  Wild type C. neoformans




 C. neoformans Xfp2 activity in the presence and 
0.5 substrate 
µmol of product formed per 30 minute 





FIG 4.7.  Location of sites on the 
with arginine residues.  Sites 10, 14, 17, 24, and 30, labeled with arrows and marked by 
red spheres on the C. neoformans
through ligand docking simulations are predicted to in eract with PEP. 
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C. neoformans Xfp2 model in which PEP i









FIG 4.8.  C. neoformans Xfp2 dimer model.  Model generated from the B. longum Xfp 




FIG 4.9.  Effect of adenosine and AMP
compared to ATP inhibition.
substrate concentrations of F6P and P
wild type activity with no effector present
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-PCP on C. neoformans Xfp2 activity 
  Reactions were performed in triplicate using 
i.  Activity is reported in percentage where 100% is 






FIG 4.10.  Effect of AMP-PCP on 
pH 7.0 (black).  Reactions were performed in triplicate using K
concentrations of F6P and Pi.  Activity is reported as percentage where 100% is wild type 
activity at pH 5.5 in the absence of effector.
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FIG 4.11  Effect of the presence of both AMP
activity.  Reactions were performed in triplicate using 
F6P and Pi.  Activity is reported in percent where 100% is wild type activity in the 
absence of effector.   
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-PCP and ATP on C. neoformans






FIG 4.12.  Location of R571 residue on the 
two large red spheres mark the two active sites of the Xfp2 dimer.  The R
colored green on one of the two monomers and yellow on the other.  
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C. neoformans Xfp2 dimer model.




  The 
135 
 
CHAPTER 5  
CONCLUSIONS AND FUTURE WORKS 
 
  This dissertation describes the first characterization of a eukaryotic xylulose 5-
phosphate/ fructose 6-phosphate phosphoketolase (Xfp) from the pathogenic fungus 
Cryptococcus neoformans.  Xfp is believed to partner with acetate kinase (Ack) to 
produce acetate during cryptococcal infection.  Studies have shown that acetate is one of 
the most abundant metabolites produced during cryptococcosis.  In addition, Xfp and Ack 
have been shown in several different studies to be expressed and/or upregulated in C. 
neoformans during infection, and an Xfp2 homolog has been shown to be required for 
full virulence in the insect fungal pathogen Metharizium anisopliae.  If the Xfp-Ack 
pathway does prove to be important during C. neoformans infection, this pathway could 
be utilized as a possible drug target as these enzymes are not present in humans.   
C. neoformans Xfp2 displayed substrate cooperativity in the form of positive 
cooperativity for fructose 6-phosphate (F6P) and xylulose 5-phosphate (X5P) and 
negative cooperativity for Pi.  Additionally, C. neoformans Xfp2 was found to be an 
allosteric enzyme inhibited by ATP, phosphoenolpyruvate (PEP), oxaloacetic acid 
(OAA) and glyoxylate and activated by AMP.  Studies showed that PEP and OAA share 
the same or possess overlapping allosteric sites on the enzyme while ATP and glyoxylate 
bind at separate sites.   Regulation by AMP:ATP levels seem to support a partnership 
between Xfp2 and Ack in producing acetate and ATP while inhibition by PEP, OAA, and 
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glyoxylate seem to suggest an indirect connection between the Xfp-Ack pathway and 
gluconeogenesis and the glyoxylate cycle respectively (Figure 5.1).   
 Even though bacterial Xfps have previously been characterized, there is no report 
that any of these enzymes display either substrate cooperativity or allosteric regulation.  
The Lactobacillus plantarum Xfp was purified and characterized specifically to 
determine if this enzyme displayed substrate cooperativity or allosteric regulation.  L. 
plantrum Xfp displayed substrate cooperativity in the form of negative cooperativity for 
Pi and was found to be an allosteric enzyme inhibited by PEP, OAA and glyoxylate but 
unaffected by the primary C. neoformans Xfp2 allosteric effectors, ATP and AMP.  Like 
with C. neoformans Xfp2, PEP and OAA bind at the same or overlapping sites on L. 
plantarum Xfp while glyoxylate binds at a separate site.  This study provided the first 
evidence that at least some bacterial Xfps are allosterically regulated.   
 To locate the C. neoformans Xfp2 allosteric sites, a model of this enzyme was 
generated from the existing bacterial Xfp structures f om Bifidobacterium breve and 
Bifidobacterium longum.  Ligand docking simulations were performed using PEP and 
OAA within predicted binding sites.  Several sites were investigated by performing site-
directed mutagenesis on residues predicted to directly interact with PEP and OAA.  Each 
variant generated was still inhibited by PEP suggesting that those residues, and most 
likely those sites, are not involved in PEP binding.  Even though these studies have yet to 
reveal the location of the PEP/OAA binding sites, they have provided some interesting 
insights into other aspects of C. neoformans Xfp2 regulation.  For example, we 
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discovered that AMP acts as a very potent activator.  AMP was able to rescue at least 
some activity for most variants that showed a considerable decrease in activity.  AMP 
was able to fully rescue activity of the R66A variant back up to wild type activity values.  
However, one variant, R571A, showed no increase in activity in the presence of AMP.  
Therefore it is possible that we have stumbled across a residue that is part of the AMP 
allosteric site, but additional studies will be need d to show this.  In addition, the 
presence of AMP was able to overcome the decrease in C. neoformans Xfp2 activity that 
occurs at elevated pH values.  It is possible that AMP is capable of overcoming what are 
typically adverse conditions, such as single amino acid mutations and elevated pH, 
because it induces a very stable, active R state enzyme conformation.   Additionally, 
preliminary studies were performed using a non-hydrol zable ATP to see if ATP 
inhibition is dependent on ATP hydrolysis.  The non-hydrolyzable ATP did not inhibit 
the enzyme suggesting that inhibition by ATP may be dependent on ATP hydrolysis, but 
additional experiments in this area are required to etermine if this is true. 
 Future studies should focus on gaining a better understanding of C. neoformans 
Xfp2 allosteric regulation.  Ideally a crystal struct re of C. neoformans Xfp2 in the 
presence and absence of allosteric effectors will eventually be obtained.  However, to 
obtain a crystal structure, very pure, concentrated enzyme is required, and in my 
experience, very little enzyme following purification.  Future studies should focus on 
ways to generate and purify more enzyme by using different expression vectors and 
possibly a different expression system other than E. coli.  Until a crystal structure of C. 
neoformans Xfp2 is obtained, the models generated and described in this dissertation 
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provide the best resource for exploring and identifyi g the location of allosteric sites.  
However, studies utilizing the Xfp2 monomer structure have yet to reveal the location of 
the PEP/OAA binding site.  The recently obtained dimer model shows new binding sites 
formed between both monomers.  Therefore future studies should focus on new sites 
within this Xfp2 dimer model.  Also additional studies are necessary to determine if ATP 
inhibition is dependent upon ATP hydrolysis as preliminary assays using a non-
hydrolyzable ATP suggest.  Future studies should involve radiolabeled ATP and thin 
layer chromatography analysis to determine if ATP is hydrolyzed and converted to 
labeled ADP by C. neoformans Xfp2 during inhibition. 
 These studies have revealed that at least some enzym s in the Xfp family from 
both fungi and bacteria exhibit substrate cooperativity and are allosterically regulated.  
The regulation of both L. plantarum Xfp and C. neoformans Xfp2 by different allosteric 
effectors, suggests that this enzyme plays different roles in bacteria and fungi.  However, 
such tight regulation of Xfp by several different metabolic intermediates suggests that the 
production of acetyl phosphate may be an important phenomenon in both bacteria and 







FIG 5.1.  Model of how Xfp2 fits into C. neoformans cellular metabolism.  Inhibitors 
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MATERIALS AND METHODS 
Molecular Modeling 
 Discovery Studio 3.5 software (Accelrys, Inc.) was used to generate a model of 
the wild type  M. truncatula cytokinin receptor sensor domain (MtCRE1) based on the 
Arabidopsis thaliana histidine kinase 4 (AHK4) complexed with N6-isopentenyladenine 
(accession code 3T4J) from Hothorn, et al. (2011). The MtCRE1 V97I variant model was 
generated using the software’s Build Mutant function that creates an alteration at the 
specified residue and optimizes conformation of the mutated and surrounding residues.  
For both the wild type and V971 variant, the model with the lowest DOPE (Discrete 
Optimized Protein Energy) score was chosen for further analysis.  The Define and Edit 
Binding Sites From Receptor Cavities function was used to determine the active site for 
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both the wild type and variant model and the site that overlaid best with the active site of 
AHK4 was chosen for ligand docking simulations.  Ligand docking of the cytokinin 
ligand N6-isopentenyladenine within the active sites of both the MtCRE1 wild type and 
MtCRE1 V97I variant models was performed using the Dock Ligands  function that 
docks ligands within a site based on the ligand’s interaction with polar and apolar regions 






A model of the membrane external portions of wild type MtCRE1 was generated 
from AHK4 using Accelrys Discovery Studio 3.5 software (Figure 1a).   The loop (amino 
acids 95-108) containing V97 is positioned distinct from the MtCRE1 ligand binding site 
(Figure 1a). Alteration of V at position 97 to I (the cre1-4 defect) does not affect 
positioning of surrounding residues, and inspection of the overall structures did not reveal 
any major structural changes between wild type MtCRE1 and the V97I variant, however, 
the side chain of the amino acid now rotates outward from the loop (Figure 1b). Ligand 
docking simulations of N6-isopentenyladenine within the active site were performed for 
both the wild type and variant models to determine if the V97I mutation affected 
cytokinin binding.  These ligand docking simulations did not reveal any differences 
between the WT and V97I variant in primary hydrogen bo ding residues between N6-
isopentenyladenine and active site amino acids residu  (data not shown).  
  
 
Figure A.1  The amino acid change in the 
cytokinin binding pocket  (a) Ribbon diagram of the predicted tertiary structure of the 
sensor domain dimer of MtCRE1 complexed with 2iP  (yellow) based on the crystal 
structure of AHK4 (see Materials & Methods).   Amino acids altered in sensor domain 
mutants are shown in purple 
resides in a region distal to the cytokinin binding pocket highlighted in red. (b) Close up 
of red region in (a) turned 90 degrees with amino acid side chains shown in purple.  
yellow residue is V97. (c) The same close up but of the mutant structure with amino acid 
side chains in green and the V97I mutation in yellow.
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cre1-4 mutant does not affect the 
(Ljsnf2, Mtcre1-4, and Atwol-1).  The Mtcre1-4
 
 
 mutation 
The 
